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ABSTRACT
Post-implant Dosimetry Analysis of Brachytherapy Patients Using Pre and Post­
implant MRI
by
Deana Tuttle
Dr. Phillip Patton, Examination Committee Chair 
Associate Professor o f Health Physics 
University o f Nevada Las Vegas
Post-implant dosimetry analysis is a critical step in brachytherapy for identifying 
the quality o f the implant based on seed localization in relation to the volume o f the 
prostate. However, the accuracy o f post-implant dosimetry analysis is dependent on 
accurate delineation o f the prostate from surrounding tissue in post-implant CT images. 
Research has shown that adequately delineate the prostate from surrounding tissue in CT 
images is difficult, resulting in significant variation between the dose received by the 
prostate and the dose prescribed by the physician. This research compared prostate 
volumes delineated from pre-implant US, post-implant CT, and pre and post-implant MR 
images in order to develop a more reliable methodology to delineate the prostate. The 
results illustrated the superiority o f MR imaging over CT imaging in delineation of the 
prostate thereby producing more individual and mean dosimetry values, D90 and V I00, 
above their respective cut points o f 140 Gy and 85%.
ni
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CHAPTER 1
INTRODUCTION
1.1 Purpose
Permanent seed implant brachytherapy has been proven to be a successful 
treatment for patients with early stages of prostate cancer with approximately 40,000 
procedures being performed in 2000 (Potters et al. 2001). The increase in permanent seed 
brachytherapy by clinical physicians has propelled research into developing better 
methods o f detennining dose to the prostate by accurately delineating the prostate from 
surrounding tissue using computed tomography (CT) and magnetic resonance (MR) 
imaging.
Post-implant dosimetry analysis for permanent seed implant brachytherapy 
patients is a crucial step in identifying the difference in the dose prescribed by the 
physician in pre-planning to the actual dose delivered to the prostate and surrounding 
tissue during surgery. In addition, it provides the physician a means o f evaluating the 
seed distribution in relation to prostate volumes for future brachytherapy procedures. 
Though research agrees that post implant dosimetry analysis is critical for evaluating the 
quality o f the implant, currently there appears to be a lack of standard procedures or 
guidelines in post-implant dosimetry for practicing physicians (Nag et al. 2000).
Post-implant dosimetry analysis identifies the extent patients are being under or 
overdosed. Therefore, the purpose of this research is to compare the actual total dose the
1
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prostate received to the dose prescribed by the physician in Iodine-125 brachytherapy 
patients based upon prostate volume differences by (I) determining differences in 
prostate volumes calculated from pre-implant transrectal ultrasound (TRUS) images and 
pre-implant magnetic resonance (MR) images, (2) determining differences in prostate 
volumes calculated from post-implant computed tomography (CT) images and post­
implant MR images, (3) determining differences in prostate volumes by fusing pre­
implant ultrasound images with post-implant CT and MR images, (4) determining the 
differences in the D90 value, the percent o f dose delivered to 90% of the prostate volume, 
the VIGO value, the percent o f the prostate volume receiving 100% of the dose, and the 
dose prescribed by the physician in the pre-planning stage to the total dose calculated in 
the post-implant stage based upon prostate volumes differences, and (5) determine 
systematic differences in MR and CT modalities by eliminating the problem of 
delineation o f the prostate from surrounding tissue by imaging phantoms of known 
volumes.
1.2 Anatomical Characteristics of the Prostate and Surrounding Tissue 
The prostate is a chestnut-sized organ located between the bladder and urogenital 
diaphragm, just in front o f the rectum. It weighs approximately 8 grams and has the 
dimensions o f 4 cm at the base, 2 cm anterior-posterior, and 3 cm vertically. It is situated 
in the pelvis cavity just below the internal urethra orifice and the symphysis pubis and 
above the superior fascia o f the urogenital diagram. The prostate surrounds the urethra 
with the ejaculatory ducts passing through the posterior section o f the prostate from the 
seminal vesicles and connecting with the urethra (Gray et al. 1918).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The prostate is characterized by the base, apex, and four surfaces, the posterior 
surface, the anterior surface, and two lateral surfaces. The base o f the prostate is located 
inferior to the wall o f the bladder where the urethra enters the prostate’s anterior region. 
The apex o f the prostate is located at the superior fascia o f the urogenital diagram as 
shown in Fig. 1.
Vas Deferens
' \  (v3sa deferens)
i
Seminal Vesicle 
(surface view)
Seminal 
Vesicle 
(cutaway view)
Base of 
prostate
restate
Prostatic urethra
Figure 1. Illustration o f the prostate showing the seminal vesicles, prostatic urethra, apex, 
and base o f the prostate (Bostwick et al. 1994).
The posterior surface is about 4 cm from the anus and is separated from the 
rectum by its sheath and connective tissue. The anterior surface o f the prostate is located 
about 2 cm behind the pubic symphysis and is where the urethra emerges from the 
prostate in front and above the apex. The lateral surfaces o f the prostate are surrounded 
by the anterior part o f the Levator ani muscles and are separated from the muscles by an 
array o f veins (Gray et al. 1918).
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The majority o f the prostate’s mass is composed o f glandular tissue which is 
defined by zonal anatomy (Gray et al. 1918). The transition zone (TZ) is located between 
the anterior fibromuscular stroma and the peripheral zone (McLaughlin et al. 2005). 
About 20% of prostate cancer will originate in the transition zone (Rangabashyam et al. 
2001). The peripheral zone (PZ) is located between the rectum wall and the transition 
zone (McLaughlin, et al. 2005, Watson et al. 1997) and encompasses about 70% of the 
prostate gland. This zone is where 70% of prostate cancer will originate (Rangabashyam 
et al. 2001, Watson et al. 1997). The central zone (CZ) represents the tissue at the base of 
the prostate and encompasses the ejaculatory ducts located within the prostate. 
Approximately 10% of prostate cancer will originate here (Rangabashyam et al. 2001).
1.3 Permanent Seed Prostate Brachytherapy 
Permanent seed brachytherapy is the placement o f radioactive seeds in the 
prostate using interstitial brachytherapy techniques which include 3D anatomically based 
dosimetry planning and guidance from real-time diagnostic imaging. This method of 
treating prostate cancer is currently the most prescribed plan in the United States (Peschel 
et al. 2003). It is widely chosen because it is low cost, has a short recovery time, produces 
excellent long-term results from biochemical failure, and has low morbidity (Peschel et 
al. 2003). Application o f brachytherapy for treatment o f prostate cancer can be prescribed 
two ways, as a monotherap (a treatment plan with just permanent seed brachytherapy) or 
as a combination therapy (a treatment plan with permanent seed brachytherapy in 
addition to external beam radiation) (Peschel et al. 2003). In a study by Potters et al. 
(2004), prostate cancer patients were treated with radical prostatectomy, external beam
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
radiation, or permanent seed brachytherapy. Results indicate similar rates in freedom 
from biochemical failure for all three treatment plans. The overall survival was 97% for 
radical prostatectomy, with 96% for external beam, and 93% for brachytherapy. 
Compared to external beam radiation and radical prostatectomy, brachytherapy has fewer 
cases o f urinary or rectal complications and sexual dysfunction (Yu et al. 1999).
With the increase o f brachytherapy treatment as an option for many prostate 
cancer patients due to the early diagnoses obtained from monitoring PSA levels (Yu et al. 
1999), research has begun to focus on identifying the variables that affect the outcome of 
the procedure. The goal of prostate brachytherapy is to deliver the prescribed dose to the 
prostate while minimizing the dose received by the urinary and rectal areas using a 3D 
anatomically based treatment plan, an interoperative treatment plan, and an analysis of 
post-implant dosimetry (Yu et al. 1999). However, research conducted by the clinical 
research committees o f the American Brachytherapy Society (ABS) and the Prostate 
Brachytherapy Quality Assurance Group (PBQAG) conclude that there is a wide 
variation in indicators, techniques, treatment regiments, and dosimetry for treating 
prostate cancer with brachytherapy. Two major areas o f concern the committees 
addressed were pre-implant treatment planning and post-implant dosimetry analysis, both 
o f which are dependent upon being able to acquire accurate prostate volumes from 2D 
images.
1.4 Dose Margin
One factor that has been identified that contributes directly to post-implant 
dosimetry is the dose margin used for the implant (Yu et al. 1999, Waterman et al. 1998).
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Because o f uncertainties in seed distribution, the percent of the prostate volume receiving 
the prescribed dose is almost always less than what was plarmed. To ensure adequate 
dose coverage, a plarming volume larger than the prostate volume is used to ensure dose 
coverage beyond the prostate capsule. Alternatively, the physician can increase the 
strength o f the seeds or increase the number of seeds to be implanted until the prescribed 
isodose line extends several millimeters beyond the prostate (Yu et al. 1999).
The 1998 study by Waterman et al. illustrates how margin determination during 
pre-implant planning can directly affect dose coverage. In a comparison between a dose 
margin which closely contoured the pre-implant prostate volume to a standard dose 
margin that extended several millimeters beyond the periphery o f the prostate, the pre­
implant plan with little or no margin had less dose coverage than the pre-plan with a 
standard dose margin due to post-implant edema. As the prostate swelled from the edema 
after the implant, it was still covered by the isodose lines from the dose margin being 
extended past the peripheral o f the prostate capsule during the pre-planning stage 
(Waterman et al. 1998).
1.5 Edema
Edema also influences the dose coverage due to the increase in prostate volumes 
from implant trauma. Compared to pre-implant volumes, edema can increase prostate 
volume as much as 96% with an average increase in prostate volumes of 52% (Waterman 
et al. 1998). This increase in prostate volume results in an increase in the separation 
between the implanted seeds thus lowering the percentage of the prostate volume that is 
receiving 100% of the prescribed dose (Yu et al. 1999, Waterman et al. 1998, Taussky et
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al. 2005). However, a CT scan done after the edema has completely resolved will result 
in an overestimation o f the dose delivered to the prostate because the dose being 
delivered during the time the edema is resolving will not be accurately accounted for by 
the post-implant dosimetry analysis is calculated (Yu et al. 1999). Since Iodine-125 
delivers 90% of its total dose in the first 197 days after the implant, scheduling the time 
for post-implant CT scans is not only dependent upon the edema, it is also dependent 
upon the type of seed used in the implant (Yu et al. 1999, Waterman, et al. 1998). 
Therefore, a CT scan performed immediately after the implant will underestimate the 
dose delivered to the prostate while CT scans performed after all the edema has resolved 
will overestimate the dose delivered to the prostate. Studies suggest the optimal time for 
1-125 post-implant dosimetry analysis is 30 days after treatment (Yu et al. 1999, Helmick 
et al. 2002, Taussky et al. 2005).
1.6 Source Type and Source Distribution 
The two radionuclides used for low-dose rate brachytherapy are 1-125 and Pd- 
103. Both are similar in dose distribution, dimensions, and photon energy. Iodine-125 
seeds are encapsulated in titanium with outer dimensions o f 4.5 mm x 0.8 mm for the 
most commonly used type o f seed. Model 6711. Model 6711 contains 1-125 in the form 
of silver iodide deposited on the surface o f a silver rod, which serves as a radiographic 
marker. The average overall energy for all 1-125 emissions is 27.4 keV with a half-life o f
59.4 days. Since clinical studies do not show any difference in patient outcomes or 
complications with either 1-125 or Pd-103, the ABS does not make a radionuclide 
preference for prostate brachytherapy.
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There are three different types of seed distribution that can be applied in 
brachytherapy; uniform loading, modified peripheral loading, and peripheral loading. 
The uniform loading spaces the seeds 1 cm apart throughout the prostate resulting a 
higher dose in the center o f the prostate. The modified peripheral loading is similar to the 
uniform loading distribution except some seeds are deleted in the center o f the prostate to 
reduce the central dose. Peripheral loading places the seeds along the peripheral o f the 
prostate sparing the urethra from receiving unnecessary dose. Also, with 70% of prostate 
cancer being located in the peripheral zone, peripheral loading for seed distribution is the 
most commonly applied method o f source distribution. This method o f seed distribution 
can maximize the prescribed dose to the periphery o f the prostate while minimize the 
dose to the urethra (Yu et al. 1999).
1.7 Freedom from Biochemical Failure 
One o f the most important applications of post-implant dosimetry is determining 
the time in which the patient is cancer free or free from biochemical failure after 
completion o f the treatment. The success of the treatment is measured by the patient’s 
prostate specific antigen (PSA) scores, Gleason scores, and/or biopsy results. Current 
research can support evidence to directly correlate the freedom from biochemical failure 
in permanent seed implant to two post-implant parameters, D90, the dose delivered to 
90% of the prostate volume, and V I00, the amount o f prostate volume receiving 100% of 
the prescribed dose (Gong et al. 2002). O f these, the best dosimetry parameter to describe 
the amount o f dose delivered to the prostate is the D90 parameter (Nag et al. 1999). The 
D90 parameter is more commonly used instead o f the DlOO parameter because there arc
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small errors in contouring the prostate in addition to small areas within the prostate that 
have been under dosed, making the DlOO parameter an incorrect representation o f the 
actual dose being delivered to the prostate volume. In addition, D90 is the only 
dosimetric parameter that has been directly correlated to PSA response (Stock et al. 
2002).
Research has identified a D90 cut point value of 140 Gy (Polo et al. 2004, Stock 
et al. 2000, Wallner et al. 2003, McNeely et al. 2004, Merrick et al. 1999, Kollmeier et al.
2003) and a V I00 eut point o f 85% (Polo et al. 2004, Wallner et al. 2003) for 1-125 
sources using CT based dosimetry. The relationship between freedom from biochemical 
failure and D90 value is illustrated in a study by Stock et al. (1998) which showed 68% 
of patients who received a D90 less than 140 Gy were free from biochemical failure 
compared to 92% of patients who received D90 greater than 140 Gy. A similar study by 
Wallner et al. (2003) illustrated the relationship between V I00 and biochemical failure 
where 97% of the patients that had a V I00 greater than 90% were free from biochemical 
failure compared to only 87% o f the patients who had V I00 less than 90%.
In the 2004 study by Polo et al. that compared CT and CT/MR dosimetric 
parameters, D90 and V I00, showed superior results from CT/MR imaging due to volume 
definition from the MR images instead o f CT images. D90 values were only 116 Gy for 
the CT images yet the CT/MR fused images resulted in D90 values o f 158 Gy. The V I00 
also showed the same results with 82% coverage measured from the CT images 
compared to 88% coverage measured from the CT/MR fused images (Polo et al. 2004).
Research has determined the accuracy o f post-implant dosimetry analysis is 
dependent upon successful delineation o f the prostate from surrounding tissue, and that
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current imaging practices are unable to adequately produce true prostate volumes. As a 
result, MR imaging of the prostate or applying multiple imaging modalities and fusing 
the images is being proposed in this research as a method o f enhancing current post­
implant dosimetry analysis by more accurately measuring the prostate volume.
1.8 Brachytherapy Imaging Modalities
1.8.1 Pre-implant Ultrasound (US) Volume Study and Computed Tomography (CT) 
Imaging
Transrectal ultrasound (TRUS) imaging is used by praeticing clinical oncologists 
for pre-planning, implantation, and post-implant dosimetry analysis. During the pre­
planning stage, ultrasound images are obtained during a volume study two to three weeks 
before the implant using TRUS images. The volume study provides pre-implant treatment 
planning information including the number and strength o f the seeds to be implanted, grid 
coordinates for needle placement during surgery, and the dose distribution. Peripheral 
dose distribution is emphasized to reduce central hot spots in the prostate thus reducing 
urinary complications (Nag et al. 1999). The pre-implant US images obtained during the 
volume study are also used by physicians during the implant stage for seed distribution in 
relation to the border o f the prostate. For post-implant dosimetry analysis, the US images 
are fused with CT images, which provide seed localization information. Using US images 
solely for post-implant dosimetry analysis would have advantages of being more 
accurate, less expensive, and faster, than CT imaging. However, US can not be used after 
implantation because o f the frequency disruption the titanium seeds produce which 
manifests as a shadowing of the seeds farthest from the probe (Solhjem et al 2004).
10
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The optimum post-implant imaging modality would be able to determine seed 
location and to delineate the prostate from the surrounding tissue. Fusion of the pre­
implant ultrasound images to post-implant CT images are commonly used for post­
implant dosimetry analysis with the prostate volume information being supplied by the 
US and seed localization information being supplied by the CT. The posterior border of 
the prostate and urethra can be used to register the two images with the calculated isodose 
curves being superimposed on the resulting fused image (Nag et al. 1999).
The issue with applying CT imaging for fusion with US images for post-implant 
dosimetry analysis is illustrated in previous studies that show prostate volumes delineated 
from CT images are on the average 30% to 50% larger than prostate volumes delineated 
from MR or US images making the difference in prostate volumes from the CT images a 
major concern in regards to the accuracy of post-implant dosimetry analysis (Helmick et 
al. 2002, Steggerda et al. 2004, Prete et al. 1998, Solhjem et al. 2004). Even with an 
experienced oncologist, research has concluded that the contouring of prostate volumes in 
CT images is difficult and the uncertainty in adequately defining the volume can 
significantly affect the post-implant dosimetry analysis (Crook et al. 2002, Anderson et 
al. 1999).
The importance o f CT based post-implant dosimetry lay not only in being able to 
precisely delineate prostate volumes, but being able to do it consistently among different 
observers. Research has also shown that there has even been a large discrepancy in 
outlining the CT prostate volumes among different physicians. From the study by 
Narayana et al. (1995), the volumes contoured on pre-implant CT images were 13%, 
35%, and 92% larger than volumes contoured on pre-implant US images by three
1 1
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different physicians. On average, the prostate volumes defined in the pre-implant CT 
images were 47% larger and 0.6 cm longer than the volumes defined in the US images. 
The difference in prostate volumes delineated by the three observers illustrates the 
difficulty in distinguishing the prostate from surrounding tissue in CT images.
1.8.2 Computed Tomography (CT) and Magnetic Resonance (MR) Imaging
Several studies have reported large discrepancies in prostate volumes delineated 
from CT images compared to volumes delineated from US or MR images (Polo et al.
2004). In one study by Rasch et al. (1999) prostate volumes contoured from CT images 
were 30% larger than volumes contoured from MR images. Another study illustrated the 
ability o f MR imaging to accurately represent the actual volume o f the prostate (Amdur et 
al. 1999) where prostate volumes were measured using US and MR imaging prior to 
radical prostatectomy. The prostate volumes delineated from the US images were 8% 
larger and volumes delineated from the MR images were only 6% larger than the actual 
surgical specimen.
The specific problem reported with using CT imaging is the difficulty in 
delineating the apex, base, and seminal vesicles from surrounding tissue and 
distinguishing the prostate from the prostatic muscles and the periprostatic venous plexus 
(Nag et al. 1999, Dubois et al. 1998, Potters et al. 2001, Crook et al. 2004, Rasch et al. 
1999, Amdur et al. 1999, McLaughlin et al. 2002, Polo et al. 2004, Helmick et al. 2002, 
Badiozammani et al. 1999, Algan et al. 1995). Other crucial problems identified in using 
CT imaging include distinguishing the posterior section o f the prostate from the anterior 
wall of the rectum, difficulty in distinguishing between the posterior-inferior apical 
portion o f the prostate from the anterior portion of the levator ani muscles, the inclusion
12
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of neurovascular bundles as part o f the prostate, and distinguishing the superior edge o f 
the prostate from the bladder (Al-Qaisieh et al. 2002, Crook et al. 2004, Potters et al. 
2001, Roach et al. 1996, Polo et al. 2004, McLaughlin et al. 2002). The greatest area o f 
uncertainty in defining boundaries in CT images is located at the most inferior or apical 
portion of the prostate. This region is o f major concern to oncologists since 75% to 85% 
o f prostate cancers involve the apical region o f the prostate requiring optimum dose 
coverage to this area (Roach et al. 1996).
Inter-observer variation is also a significant factor when comparing the 
delineation of prostate volumes from CT and MR images. Inter-observer differences on 
CT prostate volumes were significantly larger with volume differences ranging from 35 
cm^ to 70 cm^, a 100% difference in half o f the patients in a study by Amdur et al. 
(1999). In comparing prostate volume differences using CT and MR fused images, the 
study revealed prostate volumes contoured in the CT images were 32% larger than the 
volumes contoured in the MR images.
A solution to the overestimation o f prostate volumes delineated in CT images is 
the application of MR imaging. MR imaging offers better soft tissue delineation and can 
be correlated with US evaluations and pathological results. In addition, MR imaging can 
produce better inter-observer reproducibility and fusion o f CT and MR imaging is being 
researched as a means o f assessing implant quality (Polo et al. 2004). MR imaging is 
favored over CT imaging because o f its reproducible and consistent delineation of 
prostate volumes (Crook et al. 2003). Dubois et al. (1998) showed a difference o f 18.2% 
between the mean inter-observer variations o f prostate volumes contoured on CT images 
among two different observers. However, the mean inter-observer variation in prostate
13
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volumes contoured on the MR images had an 8.3% difference and more consistency. 
Prostate volumes contoured from MR images have also shown to correlate closely with 
volumes measured from pathological examinations (Dubois et al. 1998) and are 
considered to be the gold-standard for prostate volume definition (Parker et al. 2003, 
Amdur et al. 1999).
1.9 Post-implant Brachytherapy Dosimetry Analysis 
Post-implant dosimetry is used to identify any variation in the treatment plan in 
order for the physician to evaluate the quality o f the implant by calculating the actual 
dose delivered to the prostate, urethra, rectum, and surrounding tissue (Yu et al. 1999, 
Nag et al. 1999). The post-implant dosimetry parameter used to determine the quality of 
the implant and to predict freedom from biochemical failure is D90. Studies conducted at 
Memorial Sloan-Kettering have shown the D90 dosimetry value is very sensitive to small 
differences and perturbations in the location o f the seeds and target delineation (Nag et al. 
1999). A study by Polo et al. (2004) illustrated that post-implant dosimetry is so sensitive 
to volume definition that if  prostate boundaries are enlarged on CT images by 4 mm from 
the actual volume, D90 values will decrease from 171 Gy to 98 Gy and V I00 will 
decrease from 95% to 72%, well below their respective cut points. But when permanent 
seed prostate brachytherapy is pre-planned with the sources having D90 and V I00 
dosimetry parameters greater than their cut point values, patients have a 10-year local 
recurrences-free survival rate which is twice that o f patients having dosimetry parameters 
below the cut point values (Nath et al. 1998). With post-implant dosimetry values 
dependent upon prostate volumes delineated from CT imaging with studies concluding
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
that volumes contoured from CT images are significantly overestimated, research is 
supporting the implementation o f MR imaging for prostate radiation treatment planning 
(Parker et al. 2003).
The goal o f this research is to calculate the difference in prostate volumes 
delineated from pre-implant US, post-implant CT, and pre and post-implant MR images 
to identify the impact volume definition has on post-implant dosimetry values, D90 and 
V I00.
15
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CHAPTER 2
VOLUME ESTIMATION OF 25 ML, 50 ML, AND 100 ML FLASKS USING 
COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING
2.1 Introduction
The accuracy of post-implant dosimetry analysis in the evaluation of prostate 
cancer patients depends upon being able to delineate the prostate in 2D images. The 
ability to obtain accurate prostate volumes from either CT or MR images is dependent 
upon various factors. Two such variables are differentiation o f prostate tissue from 
surrounding tissue and the problem of subjectivity. Due to poor definition of soft tissue in 
CT images, the inclusion of surrounding tissue with the delineation o f the prostate in CT 
images has resulted in an increased volume estimate that differs significantly from the 
actual volume of the prostate (Al-Qaisieh et al. 2002). Previous research has shown 
prostate volumes delineated from CT images are on the average 40% larger than prostate 
volumes delineated from other imaging modalities (Steggerda et al. 2004) raising 
questions in the accuracy o f post-implant dosimetry analysis (Helmick et al. 2002, 
Steggerda et al. 2004, Prete et al. 1998, Solhjem et al. 2004). Subjectivity has also been a 
concern in prostate brachytherapy post-implant dosimetry analysis where dosimetry 
parameters, D90 and V I00 are calculated based on delineating prostate volumes from CT 
images (Badiozamani et al. 1999). Dubois et al. (1998) showed that there are smaller 
inter and intra observer differences with volumes contoured from MR images than
16
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volumes contoured from CT images concluding that MR imaging is more precise and 
more accurate in delineating the prostate for evaluation o f permanent seed prostate 
implantation. These results suggest that the subjectivity associated with delineating 
prostate volumes on CT images makes the accuracy o f the dosimetric evaluation based on 
CT imaging questionable.
The purpose o f this portion o f the research is to determine systematic differences 
in MR and CT modalities by eliminating the problems o f subjectivity in prostate 
contouring and delineation of the prostate from surrounding tissue by imaging phantoms 
o f known volumes.
2.2 Research Methodology 
Three borosilicate volumetric flasks with defined volumes o f 25 ml, 50 ml, and 
100 ml were used as phantoms. These particular flasks were selected for their ellipsoidal 
shape which mimics the shape o f the prostate. The flasks were filled with distilled water 
and submerged in water to simulate a prostate gland inside the pelvic region (Fig. 2). The 
flasks were placed on top o f a clay pedestal to ensure the boundary between the glass 
flask and glass jar didn’t interfere with delineation in the CT and MR images. Styrofoam 
cones were bored out with the stem of the flasks placed inside to ensure stability and to 
prevent changes in the water level inside the flasks and jars.
The phantoms were imaged individually with a GE SIGNA LX EXCITE 1.5 T 
MRI scanner with a GE Toropa coil and a Medrad endorectal coil interface. The 
phantoms were scanned in the axial plane with a T2 FRFSE (Fast Recall, Fast Spin Echo
17
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sequence with an 18 cm field o f view and 24 slices o f 3.0 mm thickness. A 2D MRI slice 
o f the 50 ml flask is shown in Fig. 3.
Figure 2. 25 ml, 50 ml, and 100 ml flasks filled with distilled water and placed inside 
water phantoms.
The three flasks were also imaged with a Philips CT helical scanner in the axial 
plane with 16 slices o f 3 mm thickness with a 3 mm gap. Figure 4 shows a 2D CT image 
of the 100 ml flask. The axial T2 MR and axial CT image sets were loaded onto the 
Varian Variseed software in order to contour the flask volumes.
18
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Figure 3. A 2D 3 mm slice obtained from the MR image of the 50 ml flask filled with 
distilled water and placed inside a water phantom.
19
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Figure 4. A 2D slice extracted from the CT data set o f the 100 ml flask filled with 
distilled water and placed inside a water phantom.
2.3 Results
The results of contouring the 25 ml, 50 ml, and 100 ml flasks from MR and CT 
images are given in Table 1. The contoured volumes o f the three flasks from the CT 
images showed significant differences from the actual volumes o f the flasks. The
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contoured volume o f the 25 ml flask was 18.0 em^, a percent error of 27.9%. Similar 
results were seen with the 50 ml and 100 ml flasks. The contoured volume o f the 50 ml 
flask was 37.4 cm^, a pereent error o f 25.2% and the 100 ml flask’s contoured volume 
was 77.0 em^, a pereent error o f 23.0%.
Table 1. Volumes o f the 25 ml, 50 ml, and 100 ml flasks contoured from the CT and MR 
images along with the percent error from the original volumes in parenthesis.
Flask Volumes (ml) CT Volume (ml) MR Volume (ml)
25 18.0 (27.9) 23.3 (6.20
50 37.4 (25.2) 47.5 (5.0)
100 77.0 (23.0) 96.6 (3.4)
Compared to CT imaging, the volumes contoured from the MR images were 
closer to actual volumes o f the three flasks. The contoured volume of the 25 ml flask 
from the MR images was 23.3 cm^ or 6.8% smaller than the actual volume. The 
contoured volume o f the 50 ml flask was 47.5 em^, a 5.0% pereent error and the 
eontoured volume o f the 100 ml flask was 96.6 cm^, a 3.4% percent error. These results 
show that the volumes contoured from the CT images underestimated the actual volumes 
of the flasks from 23.0% to 27.9% but the volumes contoured from the MR images only 
underestimated the actual volumes o f the flasks by 3.4% to 6.8%.
The data also indicate that smaller contoured volumes experience larger 
differences from the actual volume in both CT and MR images. The difference o f the 25 
ml volume contoured in the CT images was 27.9% compared to 25.2% for the 50 ml flask 
and 23.0% for the 100 ml flask. Similar results were seen in the MR images with the 25
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ml flask having a percent error of 6.8% compared to the 5.0% for the 50 ml flask and 
3.4% for the 100 ml flask. Since the optimum prostate volume for brachytherapy is in the 
25 ml to 50 ml range, the larger differences seen with the delineation o f smaller volumes 
in the CT and MR images will greatly impact dosimetry analysis.
The volumes contoured from CT and MR images of the 25 ml, 50 ml, and 100 ml 
flasks are plotted versus the actual volumes of the flasks in Fig. 5. Figure 5 shows a linear 
relationship with a correlation coefficient o f 0.999 for both imaging modalities.
Flask Volumes versus Contoured CT and MR Volumes
120 n
100
80
— C T  Volumes (ml)
—  M R Volumes (ml)
100 125
Flask Volumes
Figure 5. The contoured volumes from the CT and MR images are plotted against the 
actual volumes o f the flasks illustrating a linear relationship between the flask volumes 
and the CT and MR volumes.
Graphical analysis o f the flasks in Fig. 5 shows a correlation of 0.79 to the 
volumes contoured from the CT images (blue line) and 0.98 to the volumes contoured 
from the MR images. From these results, volumes contoured from CT images will
22
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consistently be 21% smaller than the actual volume but volumes contoured from MR 
images will only be 2% smaller.
2.4 Conclusion
The discrepancy in the contoured volumes of the flasks from CT and MR images 
was larger in the CT imaged volumes than from the MR imaged volumes. The contoured 
volumes o f the flasks from the CT images were 23.0% to 27.9% smaller than the original 
volumes o f the flasks. But the contoured volumes o f the flasks from the MR images were 
only 3.4% to 6.8% smaller than the volumes o f the original flasks. These results agree 
with results of previous research showing that volumes contoured on MR images 
correlate more closely to pathological specimen (Roach et al. 1996, Polo et al. 2004, 
Frété et al. 1998, Dubois et al. 1998). Furthermore, these results illustrate why prostate 
volumes contoured from MR images are considered to be the gold-standard in prostate 
brachytherapy pre-implant dosimetry planning and in post-implant dosimetry analysis 
(Amdur et al. 1999, Parker et al. 2003).
Graphical analysis o f the three flasks show a linear relationship between the 
volumes o f the original flasks and the volumes contoured from the CT and MR images. 
Graphing the volume of the flask with the volumes contoured from the CT images 
illustrates that the CT images underestimated the volume of the flasks by 21%. However, 
graphing the volume o f the three flasks with the volumes contoured from the MR images 
shows that the MR images only underestimated the volumes by 2%.
Though there is a significant difference in the magnitude in which the CT images 
underestimated the volumes o f the flasks compared to the MR images, there was one very
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distinct similarity between the two imaging modalities. The data illustrated that the 
smaller volumes delineated in both CT and MR images had larger differences from the 
actual volumes o f the flasks than the larger volumes. The significance o f these results 
indicate that images o f prostate volumes ranging from 25 ml to 35 ml will exhibit larger 
differences in volumes contoured from MR and CT images than prostate volumes o f 40 
ml to 50 ml, making post-implant dosimetry analysis less accurate for smaller prostate 
volumes. This result is supported in a study by McNeely et al. (2004) where 20% o f small 
prostate volumes had D90 dosimetry values less than 140 Gy while medium prostate 
volumes had 9% and larger prostate volumes had only 3% less than 140 Gy.
The prostates imaged in vivo show an increase in volumes in both CT and MR 
images rather than a decrease as shown from imaging the flasks. The discrepancy in 
volume differences between in vivo imaging of prostates and imaging o f the flasks 
illustrates the difficulty in delineating prostate tissue from the surrounding soft tissue in 
the images. The results also show the CT images o f the flasks created well defined 
glass/water boundaries, eliminating any ambiguity in defining the glass from the water. 
Yet, there was still a significantly larger difference between the volumes contoured from 
the CT images than the volumes contoured from the MR images. This indicates that CT 
imaging will generate images that have a larger difference from the actual volume then 
MR images. The research illustrates how volumes contoured in MR images represent a 
more accurate definition o f the actual volumes in comparison to images contoured in CT 
images with smaller volumes experiencing larger differences than larger volumes in both 
imaging modalities.
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CHAPTER 3
COMPARISON OF ULTRASOUND, COMPUTED TOMOGRAPHY, AND 
MAGNETIC RESONANCE IMAGING FOR POST-IMPLANT 
DOSIMETRY ANALYSIS
3.1 Introduction
Post-implant dosimetry analysis for brachytherapy permanent seed implant is a 
crucial step in identifying differences in the dose prescribed by the physician in pre­
planning and the actual dose delivered to the prostate and surrounding tissue. This 
analysis identifies the extent patients are under or overdosed based on delineation o f the 
prostate volume using current imaging modalities and image fusion software. Though 
research agrees that post implant dosimetry analysis is critical for evaluating the quality 
o f the implant and is needed to improve future brachytherapy procedures, currently there 
appears to be a lack o f standard procedures or guidelines in post-implant dosimetry for 
practicing physicians (Nag et al. 2000).
Permanent seed implantation o f the prostate occurs in three stages, pre-implant, 
implant, and post-implant. In the pre-implant stage, TRUS is used to determine the 
clinical target volume (CTV). This is the standard volume used by the physician to define 
the prostate geometry for pre-implant dosimetry which allows the physician to correctly 
determine seed distribution. The ultrasound images are also used during the implant stage 
for prostate delineation and correct seed localization and distribution. However, for the
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post-implant stage, post-implant CT images have to be fused with pre-implant US images 
because physicians have difficulty in distinguishing the prostate from the surrounding 
soft tissue in the CT images used for seed localization (McLaughlin et al. 2002, Rasch et 
al. 1999, Potters et al. 2001, Yu et al. 1999, Roach et al. 1996). A CT image o f the 
prostate and surrounding tissue shown in Fig. 6 illustrates the problems with contouring 
the prostate from the surrounding tissue.
Figure 6. CT image of post-implant Iodine-125 seed implant illustrating excellent seed 
localization but poor delineation o f prostate from surrounding tissue.
To overcome the limitations o f CT imaging in defining prostate volumes, MR 
imaging is proposed in post-implant stages o f brachytherapy. Post-implant comparison 
between MR and CT imaging conducted by Dubois et al.(1998) shows MR images have 
significantly better boundary definition of prostate volumes and offers better apex 
definition than CT.
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Though tissue differentiation in MR imaging is superior to CT imaging as seen in 
Fig. 7, seed location and distribution is better defined in CT images. To resolve this issue, 
fusion of CT images for seed localization information and MR images for volume 
information is currently being investigated (Graves et al. 2001).
Figure 7. MR image of post-implant Iodine-125 permanent seed implant illustrating the 
excellent delineation of the prostate from surrounding tissue but the poor resolution of the 
seeds.
In this research, prostate volumes delineated from pre and post-implant MR images 
were compared to prostate volumes delineated from pre-implant US and post-implant CT 
to determine the differences in volume measurements among the different imaging 
modalities. After the US, CT, and pre and post-implant MR images were acquired, the 
prostate glands were contoured and the images were fused for comparison. In addition, 
the dosimetry parameters, D90 and V I00 were compared between the imaging modalities 
to identify how they are affected by the delineation o f the prostate volumes.
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3.2 Research Methodology
3.2.1 Participant Selection
Eight patients that elected to have permanent seed implant for treatment o f prostate 
cancer participated in this research. Since this research is investigating delineation of 
prostate volumes with different imaging modalities, any outside variable that would 
change the prostate volume, such as hormone therapy or external beam radiation, 
excluded patients from being able to participate.
Before the study began, approval was granted by each patient according to the 
Institutional Review Board (IRB). The research was approved by the IRB of the 
Northwest Hospital Medical Center in Tucson, Arizona on June 8, 2005.
3.2.2 Pre-implant Brachytherapy Transrectal Ultrasound Volume Study
In the pre-implant stage, the oncologist determined the patient’s prostate volume in 
using TRUS. The TRUS uses a rectal probe in conjunction with a Foley Catheter to 
introduce contrast into the urethra. The ultrasound was performed in 5 mm increments 
starting at the base o f  the prostate and continuing to the apex with the patient in a dorsal 
lithotomie position.
The pre-implant US images were used for dose distribution calculations using the 
Varian VariSeed™* Version 7.1 software and for seed distribution and seed placement 
during the implant. Figure 8 illustrates a brachytherapy dosimetry plan with isodose lines 
and seed distribution according to grid coordinates. The urethra and rectum walls are 
located in order to avoid overdosing these organs during implantation.
'  Varian Medical Systems, 3100 Hansen Way, M/S MGM, Palo Alto, CA 94304-1038
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Figure 8. Brachytherapy dosimetry pre-implant plan with isodose lines and seed 
distribution (yellow dots) according to grid coordinates that match the grid on volume 
study US images. The dosimetry pre-plan includes seed placement in peripheral loading 
pattern for urethra dose sparing.
The planning target volume (PTV) was extended 5 mm beyond the prostate 
capsule to ensure all cancer cells were dosed. The seeds were distributed according to the 
peripheral seed distribution method. The activity o f the seeds and the number o f seeds to 
be implanted were determined based on the prostate volume and surgery date with an 
average dose prescribed o f 145 Gy.
3.2.3 Pre and Post-implant MR Scans
Before the implant surgery, the patients had an MR scan at a diagnostic imaging 
center. The MR spectrometer used in this research for pre and post implant scans was a 
GE SIGNA LX EXCITE 1.5 T spectrometer with a GE Toropa coil and a Medrad 
endorectal coil interface. Each patient was scanned with an axial T2 FRFSE (Fast Recall, 
Fast Spin Echo), and axial T1 FRFSE with fat saturation. Fat saturation gave us the
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ability to change the contrast o f fatty tissue in the pelvic area to better delineate tbe 
prostate from the surrounding tissue. These MR imaging parameters were defined as the 
optimum settings to provide the best images o f the prostate and surrounding tissue. 
Parameters for the axial T2 FRFSE and the axial T1 FRFSE scans are given in Table 2.
Table 2. MR imaging parameters for pre and post-implant axial T2 FRFSE (Fast Recall, 
Fast Spin Echo) and T1 FRFSE pulse sequences.
Axial T2 FRFSE Axial T1 FRFSE
Time of Echo (TE) 85 ms 14 ms
Time of Repetition (TR) 4750 ms 375 ms
Field o f View (FOV) 18 cm 18 cm
Slice Thickness 3.0 mm 3.0 mm
Number of Slices 24 24
Time of Echo (TE) is the time between the initial pulse and the peak o f the echo. 
Time of Repetition (TR) is the time between excitation pulses. Both TE and TR are 
imaging parameters selected based upon T1 or T2 weighted imaging.
3.2.4 Implant Procedure
Approximately two to three weeks after the volume study, the patients were 
admitted to Northwest Medical Center for outpatient brachytherapy permanent seed 
implant. After being brought into the operating room and placed under general 
anesthesia, the patients were positioned in a dorsal lithotomie position. During the 
implant, ultrasound images obtained during the volume study, in addition to fluoroscopy 
imaging, were used for accurate seed placement within the prostate.
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The patients were implanted with pre-loaded Iodine-125 seeds. After 
implantation, the bladder was drained by the patient’s urologist. The patient was taken to 
post-op, brought out o f the anesthesia, and released.
3.2.5 Post-implant Procedure
Approximately 30 days after surgery, the patients returned for a post-operative 
exam. At this time each patient had a CT and MR scan. The CT scanner is a helical multi­
slice, 16 channel scanner. The images were acquired in 3 mm increments. The MR scan 
had the same parameters as the pre-implant MR scan.
The Pre-implant US, Post-implant CT, and Planning Target Volume (PTV) data 
were the only information used for patient pre and post treatment planning and analysis. 
All other images and data were used solely for research purposes.
3.2.6 Prostate Volume Delineation, Seed Localization, and Dosimetry Parameters
The prostate volumes were determined by contouring the CT images and the pre 
and post-implant MR images on the Varian Variseed software. The pre-implant 
ultrasound volumes and post-implant CT images were contoured by the oncologist 
(Observer 1). The radiologist (Observer 2) contoured the pre-implant and post-implant 
MR images. This researcher (Observer 3) contoured the pre-implant MR, post-implant 
MR, and post-implant CT images. All prostate volumes were contoured without a 
margin. The dosimetry values, D90 and V I00, were generated from the pre-implant US 
images, post-implant CT images, and post-implant MR images.
Seed localization was determined for all 8 patients on the post-implant CT images 
that were contoured by Observer 1 using the automatic seed finder on the Variseed 
software program. Seed localization was determined on the post-implant MR images
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using information from the pre-implant US volume study images and the knowledge of 
the distribution o f the seeds within the prostate according to the peripheral loading 
method. Seed localization on the post-implant MR images were determined for patients 2 
through 8. The seeds could not be successfully identified in patient one’s post-implant 
MR images due to artifacts and patient motion. Patients 3, 4, and 7 were randomly 
selected by Observer 3 for seed localization on the post-implant MR images and for 
subjectivity comparisons.
3.2.7 Image Fusion
Two sets o f image fusions were performed during this research. The pre-implant 
US images were fused with the pre-implant MR images and the pre-implant US images 
were also fused with the post-implant CT and post-implant MR images. To obtain the 
most accurate alignment of the two image sets, all of the images were aligned and fused 
with the Variseed software program using the urethra and the bony features in the pelvic 
area, with the prostate projected in the transverse, sagittal, and coronal planes. The 
images were aligned in the transverse plane by translating and rotating the images from 
the two imaging modalities in relation to each other until the prostate, urethra, and bony 
features were in agreement. Once the features were aligned in the transverse plane, the 
same process was performed in the sagittal and coronal planes. An example o f a 2D slice 
o f a fused image is illustrated in Fig. 9.
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Figure 9. Illustration o f fused axial US and CT images showing the prostate (red) with 
isodose lines, urethra (green), and rectum (blue).
3.2.8 Statistical Analysis
The difference, percent difference, mean, and standard deviation were calculated 
for prostate volumes delineated from the pre-implant US images, pre and post-implant 
MR images, and post-implant CT images.
The Paired Student’s t-test was used to determine if  there was a significant 
difference between the calculated mean volumes produced from each imaging modality. 
The Student’s t-test was calculated for (1) pre-implant US and pre-implant MR, (2) post-
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implant CT and post-implant MR, (3) pre-implant MR contoured by Observer 2 and pre­
implant MR contoured by Observer 3, (4) post-implant CT contoured by Observer 1 and 
post-implant CT contoured by Observer 3, and (5) post-implant MR contoured by 
Observer 2 and post-implant MR contoured by Observer 3. An example o f the 
calculations o f the paired Student’s t-test for pre-implant US and pre-implant MR is 
given in Appendix I.
3.3 Results
3.3.1 Patient Information
Table 3 lists the age, number o f needles, number o f seeds, activity per seed, total 
activity, dose, and planning target volume (PTV) for the eight patients in this study. The 
PTVs were determined by the physician during pre-implant planning and includes a 5 
mm margin added to the gross tumor. Each patient’s cancer stage fell into the T la  to T ic  
range with Gleason scores o f 6 and PSA scores ranging from 2.0 ng/ml to 10.0 ng/ml. 
The majority o f the prostate cancer was located at the right apex or right mid-base with 
two patients having the cancer located at the left mid-gland and left base.
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Table 3. Patient demographics and treatment details for all eight patients in the study.
ID # Age Needles Seeds Activity per 
Seed (mCi)
Total Activity 
(mCi)
Dose
(Gy)
PTV
(cm^)
1 65 34 112 0.338 35.806 145 58 69
2 71 30 94 0.383 33.153 145 50.92
3 61 31 n o 0.353 36.687 145 57.72
4 59 32 116 0338 37.158 145 5838
5 62 38 100 0.325 30368 145 49.06
6 60 40 114 0.354 40.394 145 66.37
7 74 34 107 0333 3332 145 53.55
8 66 30 103 0.357 34.599 145 54.83
3.3.2 Pre-implant US and Pre-implant MR
The pre-implant US mean prostate volume was 37.9 cm^ with a standard 
deviation o f 4.5 cm^. The pre-implant MR mean volume was 41.5 with a standard 
deviation o f 7.7 cm^. In comparing these mean prostate volumes, the pre-implant MR 
volumes mean is 3.6 cm^ or 9.5% larger than the pre-implant US volumes mean. Since 
prostate volumes contoured from MR images are considered to be the gold standard in 
brachytherapy, the prostate volumes means from pre-implant US images underestimate 
the correct volume mean by 9.5%. Table 4 lists the contoured volumes from the pre­
implant US, pre-implant MR, post-implant CT, and post-implant MR images.
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Table 4. Individual and mean prostate volumes with standard deviation contoured from 
the pre-implant US, pre-implant MR post-implant CT, and post-implant MR images for
Patient
ID #
Pre-implant 
US Volume 
(cm^)
Pre-implant 
MR Volume 
(cm^)
Post-implant 
CT Volume 
(cm^)
Post-implant 
MR Volume 
(cm^)
1 3&4 43.9 51.9 50.5
2 333 2 8 3 31.0 36.7
3 353 42.4 3T8 48.9
4 41.7 51.0 42.3 57.3
5 32.7 36 3 363 40.1
6 45.8 48.5 37.0 56.9
7 34.4 35.7 46.4 353
8 40.5 46.1 53.3 46.2
Mean 37.9 ±4.5 41.5 ±7.7 41.5 ±8.4 46.5 ± 8.4
However, the results from the Student’s t-test calculated for the mean pre-implant 
US and pre-implant MR prostate volumes was 2.25 (p= 0.058), showing that there is not 
a statistical difference between the two means at the 95% confidence interval for seven 
degrees o f freedom.
Though the means between the pre-implant US and pre-implant MR are not 
statistically different, there is a large difference among the individual prostate volumes 
delineated from the US and MR images. Patient seven had a difference of only 1.3 cm^ 
between contoured volumes. Yet patient four had a difference o f 9.3 cm^ in contoured 
volumes.
The mean and individual D90 and V I00 dosimetry values for pre-implant US are 
listed in Table 5. The mean D90 and VlOO values are 166.9 Gy with a standard deviation 
o f 9.3 Gy and 99.4% with a standard deviation of 0.79%, respectively.
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The fused image of the pre-implant US and pre-implant MR images shown in Fig. 
10 illustrates the difference in size, shape, and positioning o f the contoured prostate 
volumes from the two imaging modalities. The prostate volume delineated in the pre­
implant MR image extends further out from the contoured volume of the pre-implant US 
image, resulting in a larger volume. It is also less uniform in shape and positioned more 
anterior and to the patient’s left in relation to the prostate delineated in the pre-implant 
US. The urethra is shown in green with a virtual seed as a green dot with red and green 
concentric circles.
Table 5. Individual and mean D90 and VlOO dosimetry values for pre-implant US, post- 
implant CT, and post-implant MR images for the eight patients._______________________
Pre-implant US Post-implant CT Post-implant MR
Patient D90 (Gy) VlOO (%) D90 (Gy) VlOO (%) D90 (Gy) VlOO (%)
1 165.1 100.0 128.1 833 NA NA
2 158.9 99.6 152.4 91.5 136.2 883
3 177.2 100.0 133.8 863 164.4 933
4 160.4 99.0 137.0 8633 121.5 79.9
5 155.8 97.7 114.2 75.2 138/2 883
6 162.6 100.0 120.9 78.4 163.4 94.2
7 180.7 99/2 99 6 75.6 186/2 98 3
8 174.4 993 106.5 78.1 147.0 906
Mean 166.9+9.3 99.4+0.79 124.0±17..3 81.9±5.9 151.0+21.8 90.3+5.8
37
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Pre-impiant MR
Pre-implant US
Figure 10. Fused image o f pre-implant US (dark red line) with isodose line (light blue 
line) and pre-plant MR (red line) illustrating the difference in size, shape, and positioning 
o f the prostate volumes delineated in the two imaging modalities. The urethra is 
illustrated in green with a virtual seed in green with concentric green and red circles.
3.3.3 Pre-implant US, Post-implant CT, and Post-implant MR
The mean post-implant CT prostate volume was 41.5 cm^ with a standard 
deviation o f 8.4 cm^. The mean prostate volume contoured from the post-implant MR 
images was 46.5 cm^ with a standard deviation o f 8.4 cm^. Table 4 lists the individual 
mean prostate volumes delineated from the post-implant CT and post-implant MR images 
for all the patients in the study.
The mean prostate volume contoured from the post-implant CT images were 
similar in size to the mean pre-implant US prostate volume o f 37.9 cm^ and identical to
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the mean prostate volume contoured from the pre-implant MR images o f 41.5 cm^. The 
least difference in individual prostate volumes between the pre-implant US and post­
implant CT of 0.4 cm^ was seen in patient four with the largest difference o f  13.5 cm^ 
from patient one. However, the mean prostate volume contoured from the post-implant 
MR images was larger than the mean from either the pre-implant US or post-implant CT 
images. But a similar difference in the individual prostate volumes between the pre­
implant US and post-implant MR is seen with 1.4 cm^ from patient seven and 15.6 cm^ 
from patient four.
In comparing the results o f the mean prostate volumes among these three imaging 
modalities, the mean pre-implant US volume was 9.5% or 3.6 cm^ smaller than the post­
implant CT volumes and 22.7% or 8.6 cm^ smaller than the post-implant MR volumes. 
The data also shows a difference between post-implant CT and post-implant MR of 
12.0% or 5.0 cm^ with the CT volumes smaller than the post-implant MR volumes. 
However, the result o f the Student’s t-test for post-implant CT and post-implant MR is 
1.30 (p= 0.235) indicating that there is no statistical difference between their means. 
Though the post-implant CT and post-implant MR means are not statistically different, 
the individual volumes varied greatly. The prostate volumes contoured from the CT and 
MR images o f patient one varied by only 1.4 cm^. However, the prostate volumes 
contoured from the CT and MR images of patient six varied by 19.9 cm^.
The fused image of the pre-implant US, post-implant CT, and post-implant MR 
images shown in Fig. 11 illustrate the volume differences between the US image and the 
CT image. Figure 11 also shows how the CT contouring excludes seeds from the 
delineated prostate while the MR image matches the shape and contours o f the US image.
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This indicates that MR images are more accurate in representing the actual dimensions of 
the prostate than CT images.
Pre-implant US
Fost-impiant CT
Post-implant MR
Figure 11. Fused pre-implant US (yellow), post-implant CT (red), and post-implant MR 
(burgundy) images illustrating the difference in prostate volumes between the three 
different imaging modalities.
Though there was not a significant difference in the pre-implant US and post- 
implant CT prostate volumes, there is a difference between their dosimetric values. The 
results o f the mean D90 values for pre-implant US, post-implant CT, and post-implant 
MR listed in Table 5 show a difference of 34.6% between pre-implant US and post- 
implant CT values. However, there was only a difference o f 10.5% between the pre­
implant US D90 and the post-implant MR D90 values even though the largest difference 
in prostate volumes was between these two imaging modalities. The mean D90 o f 151.0
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Gy with a standard deviation o f 21.8 Gy for MR imaging is also above the cut point of 
140 Gy but the D90 for CT is only 124.0 Gy with a standard deviation o f 17.3 Gy. 
Similar resNts are seen with the VlOO values. The CT mean VlOO value is 81.9% with a 
standard deviation o f 5.9% which is below the VlOO cut point of 85% while the MR 
mean VlOO value is 90.3% with a standard deviation of 5.8%.
In identifying the number o f D90 dosimetric values for the CT and MR imaging 
modalities that were above an established cut point o f 140 Gy, the results show post- 
implant CT imaging generating only one out o f eight D90 values above the cut point 
while post-implant MR imaging had four out of seven. Additionally, at a cut point o f 
85% for VlOO, post-implant CT imaging had only three out o f eight VlOO values that 
were above the cut point while post-implant MR imaging had six out of seven. With the 
correlation o f freedom from biochemical failure to D90 values greater than 140Gy and 
VlOO values greater than 85%, these results indicate that MR imaging offers more 
accurate dosimetry analysis than CT imaging.
The difference in the individual D90 values between the pre-implant US and post- 
implant CT ranged from 6.5 Gy for patient two to 81.1 Gy for patient seven. The 
difference in the individual VlOO values ranged from 8.1% also for patient two to 22.2% 
for patient five. However, a smaller difference was seen in the individual D90 values 
between the pre-implant US and post-implant MR with values ranging from 0.9 Gy for 
patient six to 27.4 Gy for patient eight. The individual VlOO values that range from 1.2% 
for patient seven to 19.1% for patient four. There was also a larger difference in the 
individual D90 and VlOO values between post-implant CT and post-implant MR imaging. 
The least difference between these two imaging modalities in the D90 values was seen in
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patient four with 15.5 Gy with the largest difference o f 83.6 Gy for patient seven. The 
least difference was seen in patient two with 3.3% and the largest difference was 22.4% 
for patient seven.
3.3.4 Pre-implant MR, Post-implant CT, and Post-implant MR
Though pre-implant US images are currently being used for pre-treatment 
planning, pre-implant MR images could offer better prostate definition resulting in more 
accurate dose coverage. In comparing the difference between the mean prostate volume 
Ifom the pre-implant MR to the mean prostate volume from the post-implant CT, the two 
imaging modalities had the same mean o f 41.5 cm^. But the difference between the pre­
implant US and post-implant CT was 9.5%. The ability to easily contour prostate 
volumes in MR images is illustrated in the comparison between the mean pre-implant 
MR volume of 41.5 cm^ and the mean post-implant MR volumes of 46.5 cm^. The 
difference between the volumes contoured from the pre-implant MR and post-implant 
MR images was only 6.0 cm^ or 12.0% compared to a difference o f 8.6 cm^ or 22.7% 
between the pre-implant US and post-implant MR.
3.4 Subjectivity
3.4.1 Pre-implant Prostate Volumes
To determine the extent subjectivity affects prostate volume delineation, different 
observers contoured the images of the prostate from different imaging modalities. Results 
illustrate very little difference in the mean value among different observers for MR 
imaging as shown in Table 6. The mean pre-implant MR prostate volume contoured by 
Observer 2 was 41.5 cm^ with a standard deviation o f 7.6 cm^ compared to a mean pre-
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implant MR prostate volume contoured by Observer 3 of 40.3 cm^ with a 5.8 cm^ 
standard deviation. This resulted in a 3.0% difference between the mean prostate volumes 
with the volumes contoured by Observer 2 being larger. A Student’s t-test for the mean 
pre-implant MR volumes showed that there wasn’t a statistical difference between their 
means with a t-value o f 1.16 (p= 0.283). Little difference was seen among the individual 
prostate volumes contoured by Observer 2 and Observer 3 from the pre-implant MR 
images. Patient three had the least difference of only 0.4 cm^ and patient two had the 
largest difference o f 5.1 cm^.
Table 6. Individual and mean pre-implant MR prostate volumes with standard deviation 
contoured by Observer 2 and Observer 3.
Patient
ID #
Pre-implant MR 
(Observer 2) 
Volume (cm^)
Pre-implant MR 
(Observer 3) 
Volume (cm^)
1 43.9 3&5
2 2R2 3T3
3 42.4 428
4 51.0 4fr9
5 3&2
6 4&5 47.4
7 35.7 3T3
8 46.1 43.4
Mean 41.5 ±7.6 40.3 ± 5.8
3.4.2 Post-implant Prostate Volumes
The effect of subjectivity was more evident in the contouring of prostate volumes 
in the post-implant CT images as shown in Table 7. The mean post-implant CT prostate 
volume contoured by Observer 1 was 41.5 cm^ with a standard deviation o f 8.4 cm^ and 
the mean post-implant CT prostate volume contoured by Observer 3 being 61.3 cm^ with
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a standard deviation o f 9.6 cm^. This shows a difference in means between the 
contouring o f the two CT images o f 47.7% with larger volumes resulting from Observer 
3. However, the mean post-implant MR prostate volume contoured by Observer 2 o f 46.6 
cm^ with a standard deviation o f 8.4 cm^ was very similar in size to the mean post­
implant MR prostate volume contoured by Observer 3 of 48.7 cm^ with a standard 
deviation o f 7.1 cm^. This shows a difference o f 4.7% with the larger volumes resulting 
from Observer 3. The individual and mean prostate volumes for the two post-implant MR 
images are also given in Table 7.
Table 7. Individual and mean post-implant prostate volumes with standard deviation 
calculated from CT and MR images by different observers for the eight patients in the 
study.
Patient
ID #
CT Volume 
Observer 1 
(cm^)
CT Volume 
Observer 3 
(cm^)
MR Volume 
Observer 2 
(cm^)
MR Volume 
Observer 3 
(cm^)
1 51.9 65 ^ 50.5 50.1
2 31.0 52.4 3fr7 37.4
3 3T8 58.1 4 2 9 50.3
4 423 74.8 57.3 58.1
5 36.0 50.7 40.1 41.7
6 37.0 725 56 9 56.4
7 46.4 52.0 328 44.7
8 523 6 3 ^ 422 50.6
Mean 41.5 ±8.4 61.3 ±9.6 46.6 ± 8.4 48.7 ±7.1
The difference in the individual prostate volumes contoured from two post­
implant CT images varied the most with a difference of 5.6 cm^ for patient seven to 36.5 
cm^ for patient six. Smaller individual differences were seen between the prostate
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volumes contoured from the two post-implant MR images with a difference o f 0.4 cm^ 
for patient one and a difference o f 8.9 cm^ for patient six.
O f the four mean post-implant prostate volumes, the prostate volumes contoured 
by Observer 3 from the CT images was the largest with 61.3 cm^ with 48.7 cm^ 
contoured by Observer 3 from the MR images followed by 46.5 cm^ contoured by 
Observer 2 from the MR images. The smallest mean o f 41.5 cm^ was contoured from the 
CT images by Observer 1. These results illustrate MR imaging as having the least 
variability among different observers compared to CT imaging, providing consistent 
volume definition among different observers.
A large difference among different observers in delineating prostate volumes in 
CT images is illustrated in the results o f the paired Student’s t-test. The result for the 
mean CT volumes contoured by Observer 1 and Observer 3 was 5.15 (p= 0.001) 
indicating a significant statistical difference at the 99% confidence interval using seven 
degrees o f freedom. However, the paired Student’s t-test for the mean MR volumes 
contoured by Observer 2 and Observer 3 was 1.90 (p= 0.099). This indicates no statistical 
difference between the two means from the different MR images.
The mean D90 and V I00 values calculated from CT images by Observer 1 and 
Observer 3 are given in Table 8. This shows very similar results with a difference of 
7.5% between the mean D90 values and a difference of 3.9% between the mean V I00 
values. The two post-implant CT mean D90 values were below the cut point o f 140 Gy 
with dosimetry values o f 124.0 Gy with a standard deviation o f 17.3 Gy and 133.3 Gy 
with a standard deviation o f 9.0 Gy. The mean V I00 value for post-implant CT contoured 
by Observer 1 was also below the 85% cut point with 81.8% with a standard deviation of
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5.9%. The only mean dosimetry value above the cut point was the mean V I00 value from 
the post-implant CT contoured by Observer 3 o f 85.8% with a standard deviation of 
3.3%.
There was also a large difference between the individual D90 values from the CT 
images ranging from 0.41 Gy for patient four to 24.4 Gy for patient five. A similar 
difference was also seen between the V I00 values with a 0.2% difference from patient 
four to 12.7% difference from patient five.
Table 8. The individual and mean D90 and V I00 values for post-implant CT images 
contoured by Observer 1 and Observer 3 for all eight patients in the study._____________
Post-implant CT 
(Observer 1)
Post-implant CT 
(Observer 3)
Patient ID# D90 (Gy) V I 00(% ) D90 (Gy) V I 00 (%)
1 128.1 83/7 125.1 79J
2 152.4 91.5 132.9 828
3 133.8 823 1422 892
4 137.0 820 137.1 86.2
5 114.2 722 1326 829
6 120.9 724 143.9 89.4
7 99.6 75.6 119.4 83.1
8 106.5 721 126.1 843
Mean 124.0+17.3 81.8±5.9 133.3+9.0 85.8+3.3
The number o f patients who had D90 values above the cut point of 140 Gy for the 
post-implant CT contoured by Observer 1 was one out o f eight with the post-implant CT 
contoured by Observer 3 having only two out o f eight. The number o f V 100 values from 
the volumes contoured by Observer 1 above 85% was three out eight. The number of 
V I00 values from the volumes contoured by Observer 3 above 85% was five out o f eight.
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A comparison o f the D90 and V I00 calculated from volumes obtained from MR 
images contoured by Observer 1 and Observer 3 from three randomly selected patients 
shows smaller differences than those seen from CT images. The mean D90 and V I00 
values calculated from contours produced by Observer 2 and Observer 3 from post­
implant MR images are listed in Table 9. Comparing the mean MR D90 value contoured 
by Observer 2 o f 157.4 Gy with a standard deviation o f 32.9 Gy and the mean MR D90 
value contoured by Observer 3 o f 153.9 Gy with a standard deviation of 18.8 Gy, there 
was only a difference of 2.3%. And a difference of only 1.4% was calculated between the 
mean MR V I00 value contoured by Observer 2 o f 90.4% with a standard deviation of 
9.4% and the mean MR V I00 value contoured by Observer 2 o f 91.7% with a standard 
deviation o f 4.5%. Not only were there smaller differences between the post-implant MR 
D90 and V I00 means compared to the post-implant CT D90 and V I00 values, but all the 
mean D90 and V I00 dosimetry values for both post-implant MR images were above their 
respective cut points o f 140 Gy and 85%.
Table 9. Individual and mean dosimetric values, D90 and V I00, o f the post-implant MR 
images calculated from contours produced by Observer 2 and Observer 3 for three
Post-implant MR 
(Observer 2)
Post-implant MR 
(Observer 3)
Patient ID# D90 (Gy) V I 00(% ) D90 (Gy) V I 00(% )
3 164.4 933 175.5 927
4 121.6 79 9 141.5 883
7 186/2 98 0 144.8 89 9
Mean 157.4+32.9 90.4+9.4 153.9+18.8 91.7±4.5
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In addition, there were more individual D90 and V I00 values for both post­
implant MR images that were above their respective cut points than the individual D09 
and V I00 values for both post-implant CT images. The post-implant MR contoured by 
Observer 2 had four out o f seven D90 values above 140 Gy and six out of seven V100 
values above 85% as shown in Table 5. Similar results were seen with the post-implant 
MR contoured by Observer 3 with three out o f three D90 and three out of three V I00 
values that were above their respective cut points as shown in Table 9.
Though the mean D90 and V I00 values were similar, there was a large difference 
seen in the individual D90 and V I00 values between the two post-implant MR images. 
The least D90 difference of 11.1 Gy was seen in patient three with the largest difference 
o f 41.4 Gy from patient seven. Similarly, the least V I00 difference o f 3.4% was also seen 
from patient three with the greatest difference o f 8.4% from patient four.
Compared to the two post-implant CT mean and individual D90 and V I00 values, 
the two post-implant MR had mean dosimetry values and more dosimetry values above 
their respective cut points. This suggests MR imaging is capable of providing more 
consistent volume information resulting in better dosimetry information compared to CT 
imaging.
3.5 Dose-volume Histograms (DVH)
Dove-volume histograms (DVH) are a crucial analytical tool for providing 
qualitative information of dose distribution and dose coverage to the prostate. DVH were 
generated from the pre-implant US, post-implant CT, and post-implant MR images for 
patients one through six for comparison to the dose coverage for the PTV. The ability to
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accurately delineate the prostate volumes from the different imaging modalities will 
produce greater dose coverage to the volumes.
The DVH were used to determine the amount o f prostate volume that received the 
prescribed dose o f 145 Gy from delineation o f the prostate volumes from the pre-implant 
US, post-implant CT, and post-implant MR images. The dose coverage to the prostate is 
determined by locating the prescribed dose o f 145 Gy on the independent axis and 
measuring the volume associated with this value on the individual lines o f the DVH.
From the six patients in the research that had DVH generated from prostate 
volume information, five patients’ DVH showed the dose coverage from the post-implant 
MR images were superior over the dose coverage from the pre-implant US or post­
implant CT images. The DVH in Fig. 12 is from patient three. From this DVH at the 145 
Gy prescribed dose, the prostate volume from the post-implant MR images (blue line) 
had a dose coverage o f 38.5 cm^ compared to 33.8 cm^ from the pre-implant US images 
(light blue line) or 29.1 cm^ from the post-implant CT images (red line). Compared to the 
PTV prostate volume o f 52.3 cm^ (burgundy line) for this patient, the post-implant MR 
imaging offered better dose coverage due to better prostate volume delineation. O f the 
DVH generated for patients one through six, five DVH showed the prostate volumes 
contoured from the post-implant MR images provided better dose coverage information.
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Figure 12. DVH from patient three showing the dose coverage from the post-implant MR 
imaging (blue line) had better dose coverage at the prescribed dose o f 145 Gy than from 
pre-implant US (light blue line) or post-implant CT (red line) imaging and came closer to 
the PTV dose coverage (burgundy line).This type o f DVH was seen in patients two 
through six.
Table 10 gives the individual and mean prostate volumes receiving 145 Gy for the 
post-implant CT, post-implant MR, pre-implant US, and PTV for patients two through 
six illustrating excellent dose coverage from post-implant MR imaging. The mean dose 
coverage to the prostates from the post-implant MR imaging for the five patients was
39.1 cm^ with a standard deviation of 8.6 cm^, 34.0 cm^ with a standard deviation o f 4.4 
cm^ for the post-implant US imaging, and 30.1 cm^ with a standard deviation of 3.6 cm^ 
for the pre-implant CT imaging. Compared to the mean PTV dose coverage o f 48.5 cm^ 
with a standard deviation o f 6.6 cm^, post-implant MR imaging provided better dose 
coverage to the prostates than the pre-implant US or post-implant CT imaging.
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Table 10. The individual and mean prostate volumes covered at the prescribed dose of 
145 Gy for the post-implant CT, post-implant MR, pre-implant US, and PTV for five out 
o f six patients.
Patient
ID# Post-implant CT 
Volume (cm^)
Post-implant 
MR 
Volume (cm^)
Pre-implant
US
Volume (cm^)
PTV 
Volume (cm^)
2 2&3 32.7 326 48.0
3 29.1 3&5 328 523
4 36.4 49.5 328 53.7
5 27.4 2 90 27.5 325
6 2 9 J 45.9 37.4 51.7
Mean 30.1+3.6 39.1+8.6 34.0+4.4 48.5+6.6
The only DVH that showed the prostate volume delineated from the post-implant 
CT imaging as providing better dose coverage than post-implant MR or pre-implant US 
imaging was generated from patient one. The DVH for patient one is shown in Fig. 13. In 
this DVH, the dose coverage from the post-implant CT imaging o f 43.5 cm^ was closer to 
the dose coverage from the PTV of 51.6 cm^. This DVH also shows the prostate volume 
from the post-implant CT images received more dose coverage at the prescribed dose of 
145 Gy than from the volumes delineated from the pre-implant US images of 35.5 cm^ or 
from the post-implant MR images o f 39.1 cm^.
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Figure 13. DVH from patient one showing the dose coverage from the post-implant CT 
(red line) came closer to the PTV dose coverage (burgundy line) than from the pre­
implant US (light blue line) or post-implant MR (blue line). This was the only type of 
DVH among the six patients.
Comparing the prostate volumes contoured from the pre-implant US, post-implant 
CT, and post-implant MR images shown in Table 4, the volumes contoured from the MR 
images were larger than the US or CT images for patients two through six. However, for 
patient one, the prostate volume contoured from the post-implant CT images was larger 
than the volumes contoured from the US or MR images. This result is illustrated in the 
superior dose coverage to the prostate from MR imaging in Fig 12.
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3.6 Conclusion
The results o f this research determined that there was a significant difference from 
the prostate volumes delineated from the pre and post-implant MR images to prostate 
volumes contoured from the pre-implant US or post-implant CT images.
There was a 9.5% or 3.6 cm^ difference between the prostate volumes contoured 
from the pre-implant US images to the volumes contoured from the pre-implant MR 
images. The difference in the individual prostate volumes between the pre-implant US 
and pre-implant MR ranged from 1.3 cm^ to 9.3 cm^. The fused image of the prostate 
from the pre-implant US and pre-implant MR images show the prostate delineated in the 
MR image extending more anterior and to the patient’s left in relation to the prostate 
delineated in the pre-implant US images. This illustrates that almost 10% of the prostate 
volume is not accounted for in the pre-treatment planning stage o f brachytherapy.
In comparing the means of the prostate volumes contoured from the pre-implant 
US to the volumes contoured from the post-implant CT images, there was also a 
difference o f 3.6 cm^ or 9.5%, suggesting that, on average, the images contoured from 
CT images produced similar volume estimates. However, the D90 dosimetry values for 
the CT imaging were suboptimal with a difference o f 34.6% between pre-implant US and 
post-implant CT values. In addition, the post-implant CT imaging had only one out of 
eight D90 value above the cut point o f 140 Gy and three out o f eight VIGO values above 
the cut point o f 85%. Even the mean D90 o f 124.0 Gy and the mean V I00 values of 
81.9% from the post-implant CT images were below their respective cut points. These 
differences are due to seeds being located outside the volume contoured on the CT 
images suggest poor contouring due to poor prostate definition.
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The prostate volumes contoured from the post-implant MR images were 
significantly larger than the volumes from pre-implant US images probably due to 
edema. Compared to the mean pre-implant US prostate volumes, the mean prostate 
volume from the post-implant MR images was 22.7% or 8.6 cm^ larger. However, there 
was a difference of only 10.5% between the pre-implant US and the post-implant MR 
D90 values. The post-implant MR images also provided more individual D90 and V I00 
values above their respective cut points with four out o f seven D90 values above 140 Gy 
and six out o f seven V I00 values above 85%. Even the mean D90 value of 151.0 Gy and 
the mean V I00 value o f 90.3% for the post-implant MR were above their respective cut 
points.
Though the mean prostate volumes differed, the difference in the individual 
prostate volumes between the pre-implant US, post-implant CT, and post-implant MR 
was similar. The least difference in the individual prostate volumes was 0.6 Gy between 
the US and CT with 1.4 Gy between CT and MR and between US and MR. The largest 
difference in the individual prostate volumes was between the CT and MR of 19.9 Gy 
followed by 15.6 Gy between US and MR and 13.5 Gy between US and CT. However, 
the same can not be said for the difference between the individual D90 and V I00 values 
for the post-implant CT and post-implant MR with the least difference in the D90 values 
o f 15.5 Gy with the largest difference o f 83.6 Gy. The same was seen in the VlOO values 
with the least difference of 3.3% and the largest difference o f 22.4%. A large difference 
was also seen in the individual D90 and VlOO values between the pre-implant US and 
post-implant CT with D90 values ranging from 6.5 Gy to 81.1 Gy and VlOO value 
ranging from 8.1% to 22.2%. The smallest difference in the individual D90 and VlOO
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values between the pre-implant US and post-implant MR images with the D90 values 
ranging from 0.9 Gy to 27.4 Gy and the VlOO values ranging from 1.2 to 19.1%.
The ability to distinguish prostate volumes in MR imaging provides more 
accurate volume definition than CT imaging resulting in better dose coverage as 
illustrated in the DVH. In five of the six DVH generated from the research, prostate 
volumes contoured from MR imaging resulted in superior dose coverage to the prostate 
compared to volumes contoured from CT imaging. The mean prostate volume receiving 
the prescribed dose o f 145 Gy for the post-implant MR imaging was 39.1 cm^ compared 
to 33.8 cm^ from the pre-implant US images and 30.1 cm^ from the post-implant CT 
images. This supports results from previous research that determined DVH from MR 
imaging are more accurate than from CT images (Badiozammani et al. 1999).
Results from this research also show that replacing pre-implant US imaging with 
pre-implant MR imaging would create better volume definition for pre-treatment 
planning and fusion with either post-implant CT imaging or post-implant MR imaging for 
post-implant dosimetry analysis. The mean pre-implant MR prostate volume was the 
same as the mean volume from the post-implant CT images compared to a 9.5% 
difference between the mean volume from pre-implant US and the mean volume from the 
post-implant CT volumes. Similar results were seen with the pre-implant MR and post­
implant MR, with a difference of only 12.0% compared to 22.7% between the prostate 
volumes contoured from the pre-implant US and post-implant MR images.
MR imaging also provided better results than CT imaging for delineation of 
prostate volumes among different observers. There was only a 3.0% difference between 
the pre-implant MR prostate volumes contoured by Observer 2 and Observer 3 with a
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difference o f 4.7% between the post-implant MR prostate volumes that were contoured 
by Observer 2 and Observer 3. But a difference o f 47.7% was seen in the prostate 
volumes contoured from the post-implant CT images by Observer 1 and Observer 3. 
When identifying the number of individual D90 and VlOO values that were above their 
respective cut points o f 140 Gy and 85%, the two post-implant MR images were clearly 
superior with a total o f seven out o f ten D90 values and a total o f nine out o f ten VlOO 
values. However, the two post-implant CT images had only a total o f three out o f sixteen 
D90 values and eight out o f sixteen VlOO values that were above their respective cut 
points.
There was even a significant difference in the individual prostate volumes, D90, 
and VlOO values between the two CT images and the two MR images. The individual 
prostate volumes from the two MR images had the least difference with the smallest 
difference of 0.4 cm^ and the largest difference o f 8.9 cm^ compared to 5.6 cm^ and 36.5 
cm^ from the two CT images. However, the same can not be said o f the difference in the 
D90 values. The smallest difference in the D90 values between the two CT images was 
0.41 Gy with the largest difference o f 24.4 Gy. But the smallest difference in the D90 
values between two MR images was 11.1 Gy with the largest difference being 41.4 Gy. 
The difference in the VlOO values were less pronounced with the smallest difference 
between the two CT images of with a 0.2% and the largest difference of 12.7%.compared 
to of 3.4% and 8.4% for the two MR images.
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CHAPTER 4
CONCLUSION
4.1 Delineation o f Defined Volumes in CT and MR Images 
The results from this research showed a larger discrepancy in the contoured 
volumes from the CT images o f the 25 ml, 50 ml, and 100 ml flasks compared to the 
contoured volumes from the MR images. The contoured images o f the flasks from the 
MR images generated volumes that were smaller than the actual volume of the flasks, but 
to a lesser degree than the volumes contoured from the CT images. Though there was a 
significant difference in the magnitude in which the CT images decreased the volumes o f 
the flasks compared to the MR images, there was one very distinct similarity between the 
two imaging modalities which is crucial in prostate brachytherapy post-implant dosimetry 
analysis. The data illustrated that the contoured volume of the 25 ml flask from the CT 
and the MR images had a greater degree o f difference compared the contoured volumes 
o f the 50 ml and 100 ml flasks, suggesting that post-implant dosimetry analysis would be 
less accurate for smaller prostate volumes.
4.2 Comparison of US, CT, and MR Imaging for Post-implant Dosimetry Analysis 
The results from this portion o f the research showed that, though prostate volumes 
delineated from pre and post-implant MR images differed in comparison to prostate
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volumes delineated from pre-implant US and post-implant CT images, MR imaging 
generated more D90 and VlOO dosimetry values above their respective cut points.
The prostate volumes delineated from the pre-implant MR images differed by 
9.5% compared to the volumes contoured in the pre-implant US and post-implant CT 
images. But between the mean post-implant MR prostate volume and the mean pre­
implant US prostate volume there was 22.7% difference. Though prostate volumes 
contoured from CT images were closer to the volumes contoured from US images, the 
true shortcoming o f CT imaging for brachytherapy was seen in the dosimetry values. The 
majority o f  the dosimetry values, D90 and VlOO, from the post-implant CT images were 
suboptimal. Compared to the dosimetry values from the post-implant CT images, the 
post-implant MR images produced 44.6% more D90 values and 48.2% more VlOO values 
above their respective cut points even though the prostate volumes contoured from the 
MR images differed the greatest compared to the volumes contoured from the US images. 
Even the mean D90 and VlOO values from the post-implant MR images were above the 
cut points, but neither mean D90 nor VlOO values from the post-implant CT images were 
above the cut points. These results were illustrated in Figure 11 which showed how the 
prostate contoured from the post-implant CT image was closer in shape and size to the 
volume contoured from the pre-implant US image, but the CT contouring excluded seeds 
from the delineated prostate resulting in extremely poor dosimetry information. It also 
showed how the prostate contoured from the post-implant MR image extended beyond 
the contouring from the pre-implant US, encompassing more implanted seeds and 
producing better dosimetry information.
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The criticality o f obtaining accurate prostate volume definition relates to the 
implementation o f pre-implant US imaging for pre-treatment planning, implantation 
information, and post-implant dosimetry analysis. The results from this research suggest 
that replacing pre-implant US imaging with pre-implant MR imaging would generate 
better prostate volume definition and dosimetry information. The prostate volumes 
delineated from the pre-implant MR and the post-implant CT images had the same mean 
volume of 41.5 cm^ but there was a 9.5% difference between the prostate volumes 
delineated from the pre-implant US and post-implant CT images. In addition, there was a 
12% difference between the mean prostate volumes contoured from the pre-implant MR 
and post-implant MR images but between the mean prostate volumes contoured from the 
pre-implant US and the post-implant MR images there was a 22.7% difference. Since the 
prostate boundary is well defined in MR images resulting in a more accurate 
representation o f the true prostate volume, the 12% difference can be related to edema 
resolution. Research has shown that, on average, edema will typically resolve by 88% 
after 28 days. Since all eight o f the patients in the study had the post-implant MR scans 
performed approximately 30 days after the implant, the 12% difference between the pre­
implant and post-implant MR images can be attributed to edema. The benefit o f MR 
imaging for dosimetry analysis was also illustrated in the DVH generated from six o f the 
patients in the study. Five o f the six DVH showed dose coverage from the post-implant 
MR imaging was superior over post-implant CT and pre-implant US imaging. From the 
six DVH generated, there was only one DVH which illustrated where the dose coverage 
from post-implant CT imaging was superior to dose coverage from the post-implant MR 
imaging.
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Subjectivity is a major concern in all prostate brachytherapy post-implant 
dosimetry analysis where dosimetry parameters, D90 and VlOO are calculated based on 
delineating prostate volumes from CT images. The results from this research showed 
prostate delineation from MR imaging is less affected by subjectivity than CT imaging. 
The difference between the mean prostate volumes from the pre-implant MR images that 
were contoured by Observer 2 and Observer 3 was only or 3.0% with little difference 
between the individual prostate volumes. Similar results were obtained with the post­
implant MR images with a difference of 4.7% between the prostate volumes contoured by 
Observer 2 and Observer 3. However, a difference o f 47.7% was seen between the mean 
post-implant CT prostate volumes contoured by Observer 1 and Observer 3. 
Consequently, the difference in individual prostate volumes contoured from the two post­
implant CT images were larger compared to the difference in individual prostate volumes 
contoured from the two post-implant MR images. In addition, the post-implant MR 
images produced better dosimetry values than the post-implant CT images. The post­
implant MR images had a total o f seven out o f ten D90 values above 140 Gy and nine out 
of ten VlOO values above 85%. But the post-implant CT images had a total o f three out of 
sixteen D90 values and eight out o f sixteen VlOO values. The post-implant CT contoured 
by Observer 3 had only one additional D90 value above 140 Gy and two more VlOO 
values above 85% than the post-implant CT contoured by Observer 1 even though the 
prostate volumes contoured by Observer 1 was 47.7% larger. However, there was a larger 
difference in the individual D90 values between the two post-implant MR images than 
between the two post-implant CT images. The difference in volumes and dosimetry 
values between the two CT images illustrates that the prostate volumes contoured in CT
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images produced dosimetry values below their respective cut points. This suggests that 
subjectivity associated with delineating prostate volumes from CT images makes the 
accuracy o f the dosimetric evaluation based on CT imaging questionable, concluding that 
MR imaging is more precise and accurate in delineating prostate volumes for post­
implant dosimetry analysis.
4.3 Overall Conclusion 
The results from this research concluded that MR imaging provides more mean 
and individual D90 and VlOO values above their respective cut points than CT imaging 
due to the ability to adequately delineate the boundary of the prostate from surrounding 
soft tissue in MR images. The data also indicate that MR imaging is less affected by 
subjectivity that CT imaging. Though the prostate volumes delineated from the CT 
images were closer to the volumes from the pre-implant US images, the individual D90 
and VlOO values were suboptimal, indicating that post-implant dosimetry analysis based 
on CT imaging gives incorrect dosimetry information in regards to the quality o f the 
implant and to the patient’s rate from freedom from biochemical failure. The results of 
this research supports MR imaging for prostate brachytherapy 1-125 pre-treatment 
planning, implantation information, and post-implant dosimetry analysis by either 
replacing pre-implant US for volume information, replacing CT imaging for seed 
localization, or by fusing MR images with CT images to provide correct volume 
definition.
61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4.4 Recommendations 
The results from this research suggest the implementation o f MR imaging for pre­
treatment planning and post-implant dosimetry analysis. Implementing MR imaging for 
pre-treatment planning can provide a more accurate prostate volume definition resulting 
in optimum seed placement within the prostate. For post-implant dosimetry analysis, the 
fusion of MR imaging to provide volume information with CT imaging to provide seed 
localization information, would generate more accurate dosimetry information resulting 
in a more accurate evaluation in freedom from biochemical failure. Also, the 
development o f new MR T2-sequences could provide better seed visualize in addition to 
the excellent prostate definition in MR images thereby eliminating the need for post­
implant CT imaging.
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APPENDIX I
STUDENT’S T-TEST FOR PRE-IMPLANT US AND PRE-IMPLANT MR
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Table 11. Student’s t-test Calculation for Pre-implant US and Pre-implant MR
Patient
Pre-implant US 
(cm^)
Pre-implant 
MR (cm^)
Difference
(z)
1 3&4 432) -5.5
2 327 22 2 5.5
3 35.9 42.4 -6.5
4 41.7 51.0 -9 J
5 32.7 3&2 -3.5
6 45.8 425 -2.7
7 34.4 35.7 -1.3
8 40.5 46.1 -5.6
Z z  =29.1 
n = 8.0
z =29.1/8
= 3.6 
I j ?  = 2 4 2 4  
(Zz)^ / n
= ( 2 9 T f / 8  
= 105.9 
Zd^ = Zz^ - (Z z f  / n 
= 2 4 2 .4 - 105.9 
= 136.5 
O d ^  =  Zd^ / n  - 1 
= 136.5/8-1 
= 19.5
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&d = V (Od 
= 4.4 
On =  ( J d / V n
= 4.4 / a/8 
=  1.6
t = ^  / ffn
= 3.6 / 1.6 
= 2.25
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APPENDIX II
HUMAN SUBJECTS RESEARCH PROTOCOL
66
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Human Subjects Research Protocol
Project title: Post-implant Dosimetry Analysis o f Iodine-125 Brachytherapy Patients by
Delineation o f Prostate Volumes Using Pre- and Post-implant MR! 
Imaging
Principal Investigator/Title/Section/Branch/Institute:
Dr. Curtis Mack, MD Arizona Oncology, Tucson, Arizona 
Deana Tuttle, Graduate Student, Department o f Health Physics,
University o f Nevada, Las Vegas, NV
Associate Investigators [include name, institution, and city]:
(1) Michael Taylor, Medical Physicist, Arizona Oncology, Tucson, 
Arizona
(2) Mark Yoshino, MD, Southern Arizona Diagnostic Imaging, Tucson, 
Arizona
(3) Phillip Patton, Ph.D. UNLV, Las Vegas, Nevada
Study type (check all that apply):
X Archived biological specimens/medical information
________ Natural history; definition o f phenotype, genotype/phenotype correlation
________ Prospective linkage/gene identification, NOT providing information to
participants
________ Prospective linkage/gene identification, providing information provided to
participants
________ Social science; assessments o f knowledge, attitudes and behavior
________ Genetic counseling
________ Drugs or devices
________ Gene transfer
  Other interventions
Key Words:
Disease(s)
Prostate Cancer_________________________________________________
Population
Males-diagnosed with prostate cancer undergoing Iodine 125 seed implant
Results routinely communicated to subjects?
X No 
Yes
Research participants to he seen at:
X Arizona Oncology and Southern Arizona Diagnostic Imaging
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1. Precis: (In 400 words or fewer, describe the study objectives, population, design, 
and outcome measures)
(1) Determination o f accuracy and reproducibility of two different imaging modalities. 
This will be accomplished by comparing pre-implant Transrectal Ultrasound (TRUS) 
images with pre-implant MR images. TRUS images are used by most physicians as 
the standard measurement o f prostate volumes for pre-planning dosimetry. The MR 
images will be compared to the TRUS images to determine volume differences.
(2)Determination o f prostate volumes by comparing post-implant CT images with post­
implant
MR images. These scans will be performed to determine the extent of post implant 
prostate volume differences between the two imaging modalities.
(3) Calculating differences in dose prescribed by the physician in the pre-planning stage 
to the total dose in post-implant stage based upon prostate volume differences 
determined in pre and post-implant imaging. Using the difference in prostate volumes 
between pre-implant TRUS and MR images and between CT and MR post-implant 
images, the dose will be calculated and compared to TRUS pre-implant dose 
prescribed by the physician to determine the extent of under or over dosage of the 
prostate and surrounding tissue.
Population:
The research will image approximately 10 brachytherapy patients for pre-implant and 
post-implant prostate volume evaluation using the MRI at Southern Arizona 
Diagnostic Imaging Center . The TRUS pre-implant and CT post-implant imaging 
will be performed at Arizona Oncology.
Design and Outcome:
The images obtained from TRUS, MRI, and CT will be contoured to determine 
differences in prostate volumes. Then, based upon these differences, the total dose the 
prostate received will be calculated and compared to the prescribed dose to identify if 
under or over-dosage of the prostate has occurred on one modality contrasted with the 
other.
2. Objective and specific aims:
The accuracy of prostate post-implant dosimetry in identifying freedom of 
biochemical failure is dependent upon imaging. I propose to compare our pre-implant 
TRUS and post-implant CT images with MR pre and post-implant images to access 
the quantitative and qualitative differences. From these results, physicians will be 
able to enhance brachytherapy procedures with the goal of better delineating dose 
requirements required for a successful implant. The results o f this study may help 
determine systematic and variable differences, perhaps altering the standard of care in 
post-implant dosimetry.
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3. Brief Rationale and Background;
Post-implant dosimetry analysis is crucial in brachytherapy for determining the dose 
the prostate and surrounding tissue received from the permanent seed implants. It 
also provides the physician a means o f evaluating seed distribution in relation to 
prostate volumes for future prostate cancer patients. However, current studies 
indicate a lack of standard procedures or guidelines for physicians for post-implant 
dosimetry analysis in clinical settings (Nag et al. 2000).
Currently, during the preplanning stage o f Brach therapy a Transrectal Ultrasound 
(TRUS) is used to determine the clinical target volume (CTV). TRUS images are 
also used during surgery for correct seed localization and distribution and prostate 
delineation. For post-implant dosimetry, the imaging modality most frequently used 
is computed tomography (CT) since seeds cannot be well localized on ultrasound. 
TRUS imaging has frequency disruption and artifacts due to the metallic seed 
capsules. Though CT is one o f the most common imaging modalities, distinguishing 
the prostate base and apex regions from surrounding tissue is difficult. (McLaughlin 
et al. 2002; Rasch et al. 1999; Potters et al 2001; Anderson et al. 1999; Graves et al. 
2001; Roach, et al. 1996). As a result o f post-implant swelling and poor soft tissue 
resolution o f CT images, prostate volumes are on the average 1.4 times larger than 
the volumes determined initially in ultrasound and MR images (McLaughlin et al. 
2002; Parker et al. 2003; Roach et al. 1996). Therefore, if  CT imaging is used as the 
sole means o f evaluation in post-implant dosimetry, dose coverage of the prostate 
would be calculated to be less than what was actually prescribed in the preplanning 
stage due to the perceived increase in prostate volume. To overcome the limitations 
of CT imaging in defining prostate volume, MR imaging is proposed in pre and post­
implant dosimetry.
The significance o f post-implant analysis is for physicians to accurately quantify the 
dose delivered and then subsequently relating it to freedom of biochemical failure. 
Current researeh ean support evidence to directly correlate the freedom from 
biochemical failure in permanent seed implants to two post-implant parameters, 
D90, the dose delivered to 90% of the prostate volume, and V I00, the amount of 
prostate volume receiving 100% of the prescribed dose (Gong et al. 2002; Stock et 
al. 1998; Wallner et al. 2003. This research may assist in altering the standard of 
care in post-implant dosimetry analysis by (I) comparing prostate volumes in pre­
implant TRUS images with pre-implant MR images (2) comparing prostate volumes 
in post-implant CT images with post-implant MR images and (3) calculating the 
differenee in dose prescribed by the physician in pre-planning stage to the total dose 
in post-implant stage based upon prostate volumes determined in pre and post­
implant imaging.
4. Description of Study Population:
4.1 Estimated number o f participants, enrollment ceiling, and anticipated 
enrollment by year.
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TRUS and MR images will be performed on 3-10 Brachytherapy patients. 
Only 3 pre-im plant patients will have the MRI scan if  a pattern appears 
indicating prostate volumes for pre-implant TRUS and MR images are 
consistent with a difference o f approximately 1.07. The TRUS images will be 
obtained at Arizona Oncology office and the MR images will be obtained at 
Southern Arizona Diagnostic Imaging office. The MRI data will be 
transferred to Dicom where the prostate volumes will be contoured on 
Variseed software. Prostate volumes will be determined during the standard 
volume study by the physician.
The standard post-implant CT will be performed in addition to MRI scans for 
10 brachytherapy patients. These scans will be performed to determine the 
extend o f post implant prostate volume differences between the two imaging 
modalities. The CT images will be done at Arizona Oncology Office and the 
MR images will be obtained at Southern Arizona Diagnostic Imaging office.
4.2 Description o f clinical inclusion/exclusion criteria.
Eligible participants will be limited to males diagnosed with prostate cancer 
scheduled to undergo a prostate seed implant and who are not prescribed 
hormone therapy to reduce prostate size nor are they receiving external beam 
treatment.
4.3 Location o f study.
The study will be performed at Arizona Oncology office located at West 
Orange Grove, Building 1, Tucson, Arizona and at Southern Arizona 
Diagnostic Imaging, 1845 West Orange Grove, Suite 103, Tucson, Arizona.
4.4 Description o f recruitment strategies
Recruitment will be done by Dr. Curtis Mack, MD at Arizona Oncology 
Office.
4.5 For existing sample/data sets, note whether samples were originally collected 
for research or clinical practice. If obtained for research, include a description 
o f the original purpose of study and prior plans for sample storage. Was 
consent obtained that would be applicable to this study? (Include copy o f  
original consent forms!)
This research study is based upon identifying differences in imaging 
modalities in delineation of the prostate o f cancer patients in determining total 
dose to the organ and surrounding tissues for identifying freedom from 
biochemical failure. A consent form is included in the packet of forms for 
submittal to the IRB committee.
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4.6 Description and justification o f inclusion/exclusion o f participants.
The objectives previously stated specifies that the participants be male, and 
within the standard age o f men seen previously with prostate cancer. Patients 
undergoing hormonal treatment are excluded because the prostate volume 
changes under this additional source.
4.7 Description o f efforts to include under-represented minorities.
Not-applicable.
4.8 Description of any financial compensation. If participant withdraws early, 
describe how compensation will be modified.
Since this research is based upon pre and post implant MR imaging performed 
during standard treatment form prostate cancer, the participant will not be 
financially compensated.
Description of procedures: (Please include a flo w sh eet or chart).
5.1 Approved Drugs 
Not-applicable.
5.2 Unapproved Drugs/Device^'
Not-applicable.
5.3 Diagnostic studies 
Not-applicable.
5.4 Biological Specimens 
Not-applicable.
5.5 Medical information 
Not-applicable.
5.6 Describe questionnaires or other psychological instruments and estimate how 
long they will take to complete, and whether they address sensitive topics
Not-applicable.
5.7 Specific results that will be given to participants or their health care providers 
Not-applicable.
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5.8 Genetic counseling 
Not-applicable.
5.9 Description o f criteria for withdrawal from study.
(1) Determination of prostate volumes by comparing pre-implant TRUS 
images with pre-implant MR images.
TRUS and MR images will be performed on 3-10 Brachytherapy patients.
The TRUS images will be obtained at Arizona Oncology office and the MR 
images will be obtained at Southern Arizona Diagnostic Imaging office. 
The MRI data will be transferred to Dicom where the prostate volumes will be 
contoured on Variseed software. Prostate volumes will be determined during 
the standard
volume study by the physician.
(2) Brachytherapy Iiodine-125 Seed Implant Surgery.
Dr. Curtis Mack, MD will perform the Iodine-125 permanent seed implant at 
Northwest Medical Center. Approximate time will be 1.0 to 1.5 hours. The 
preplanning stage o f brachytherapy uses Transrectal Ultrasound (TRUS) in 
the volume study to determine the clinical target volume (CTV). TRUS 
images are also used during surgery for correct seed localization and 
distribution and prostate delineation.
(3) Post-implant examination in determination o f prostate volumes by 
comparing post implant CT images with post-implant MR images 
approximately 30 days after surgery.
The standard post-implant CT will be performed in addition to MRI scans for 
10 brachytherapy patients. The CT images will be done at the Arizona 
Oncology office and the MR images will be obtained at Southern Arizona 
Diagnostic Imaging office. The rectal coil in post-implant MR images is not 
recommended due to the need to keep consistent parameters with post-implant 
CT images that do not require rectal coils.
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Figure 14. Flow-chart o f brachytherapy implantation procedures.
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6. D escription o f  statistical considerations and/or analytic plan
In pre-implant data analysis, the prostate volumes will be compared from the 
standard Transreetal Ultrasound (TRUS) images, contoured during the 
Volume Study by Dr. Curtis Mack, MD, to volumes determined in the MR 
images. A previous study has indicated that TRUS prostate images were 
comparable in size to MRI prostate images, with a differenee o f only 1.07. 
Only 3 pre-implant patients will have the MRI scan if  a pattern appears 
indicating prostate volumes for pre-implant TRUS and MRI images are 
consistent with a differenee of approximately 1.07.
During the post-implant data analysis, prostate volumes will be compared 
from the standard CT images to MR images. Both MRI and the CT images are 
contoured using a Variseed Software program. Since soft tissue is difficult to 
distinguish on CT images, contouring the prostate to determine volume for 
dosimetry is very subjective. Post-implant swelling and poor resolution of soft 
tissue results in a prostate volume larger that the TRUS volume generally used 
in pretreatment planning. In previous studies, CT prostate volumes were on 
the average, 1.4 times larger than the volumes determined initially in 
ultrasound or MR imaging studies.
Post-implant Brachytherapy dosimetry analysis will use the data from the pre 
and post implant prostate volumes to determine the dosage to the prostate and 
surrounding tissue.
7. Description of potential benefits of study
7.1 Direct benefits to participants (physical or psychosocial)
The MRI scans are not physically or psychosocially beneficial to the patient. 
The scans are performed as a means of identifying a prostate
volume differences and are only an addition to the standard brachytherapy 
procedures.
7.2 Collateral benefit to participants (medical or genetic counseling care)
The MRI scans are not beneficial to the diagnosis or treatment o f the patient. 
The scans are being performed in conjunction with the standard Brach therapy 
Transreetal Ultrasound (TRUS) and Computer Topography (CT) scans.. 
However, additional biological and anatomical patient information obtained 
by another imaging modality increases the possibility o f identifying any 
abnormalities. In the event an investigator notices an abnormality on an MRI 
scan, a physician will be consulted as to whether the finding merits further 
investigation, in which ease the investigator will contact you and your primary 
care physician and inform you of the finding.
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7.3 Benefits to society
The accuracy o f prostate post-implant dosimetry in identifying freedom of 
biochemical failure is dependent upon imaging. This research proposes to 
compare standard pre-implant TRUS and post-implant CT images with MRI 
pre and post-implant images to access the quantitative and qualitative 
differences. The images obtained from TRUS, MRI, and CT will be contoured 
to determine differences in prostate volumes. Then, based upon these 
differences, the total dose the prostate received will be calculated and 
compared to the prescribed dose to identify if under or over-dosage o f the 
prostate has occurred. From these results, physicians will be able to modify 
brachytherapy procedures with the goal o f improving dose distributions 
perhaps increasing the life expectancy of the patients based upon improved 
D90 and V I00 values, perhaps decreasing side effects by limiting doses.
8. Description of likelihood and seriousness of harms and how safety will be 
maximized
MRI Scans:
The MRI machine uses a strong magnet and radiowaves to make images of 
the body’s interior. The scanning procedure is very much like an x-ray CT 
scan. You will be asked to lie on a long narrow couch for a certain amount of 
time (approximately 30 minutes) while the machine gathers data.
During this time you will not be exposed to x-rays, but rather a magnetic 
field and radiofrequency magnetic fields. You will not feel either. You will, 
however, hear repetitive tapping noises that arise from the MR scanner. We 
will provide earplugs or ear phones that you will be required to wear. The 
space within the large magnet in which you lie is somewhat confined, 
although we have taken many steps to relieve the "claustrophobic" feeling.
Risks:
Magnetic fields do not cause harmful effects at the levels used in the MRI 
machine. However, the MR scanner uses a very strong magnet that will 
attract some metals and affect some electronic devices. If you have a cardiac 
pacemaker or any other biomedical device in or on your body, it is very 
important that you tell the operator/investigator immediately. As metallic 
objects may experience a strong attraction to the magnet, it is also very 
important that you notify the operator of any metal objects (especially 
surgical clips), devices, or implants that are in or on your body before 
entering the magnet room. All such objects must be removed (if possible) 
before entering the magnet room. In some cases, having those devices means 
you should not have an MRI scan performed. In addition, watches and credit 
cards should also be removed as these could be damaged. You will be 
provided a way to secure these items. If you have any history o f head or eye
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injury involving metal fragments, if  you have ever worked in a metal shop, or 
if  you could be pregnant, you should notify the operator/investigator.
Subjects will be screened in the same manner as all patients having routine 
MR to exclude those with pacers and/or cerebral aneurysm clips.
If you have had a previous reaction to Gadolinium-based contrast agents or a 
history o f  severe allergies, please notify the operator/investigator.
Some o f the RF imaging eoils, imaging software and devices being used in 
your scan are not approved by the FDA but are similar to counterparts that 
have been approved by the FDA. There is a small risk of heating from the 
cables associated with these devices. Please report any heating sensation 
immediately.
The scans performed in this study are for specific research purposes and are not 
optimized to find medical abnormalities. The investigators for this project may not 
he trained to perform medical diagnosis. The investigators and Arizona Oncology 
Office and Southern Arizona Diagnostic Imaging offices are not responsible for 
failure to find existing abnormalities with these MRI scans. However, on occasion 
the investigator may notice a finding on an MRI scan that seems abnormal. When 
this occurs, a physician will be consulted as to whether the finding merits further 
investigation, in which case the investigator will contact you and your primary 
care physician and inform you o f the finding. The decision as to whether to 
proceed with further examination or treatment lies solely with you and your 
physician. The investigators and the consulting physician, are not responsible for 
any examination or treatment that you undertake based on these findings. Because 
the images collected in this study may not comprise a proper clinical MRI scan, 
these images will not be made available for diagnostic purposes.
8.1 Drugs/deviees/gene transfer 
Not-applicable.
8.2 Radiation 
Not-applicable.
8.3 Sedation 
Not-applicable.
8.4 Psychological harms (misunderstanding, anxiety, selfesteem, depression) 
Not-applicable.
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8.5 Risks to family relationships 
Not-applieable.
8.6 Discrimination 
Not-applicable.
9. Collection, monitoring, analysis and reporting of adverse events
9.1 If this is either a natural history or limited encounter protocol, explain this to 
the IRB and specify the occurrenees that will be excluded from adverse event 
reporting.
Not-applicable.
9.2 Describe plan to monitor adverse events as defined in Section 8.0 for this 
protocol, {anticipated and unanticipated, serious and non-serious)
Not-applicable.
9.3 Describe plan to report adverse events as defined for this protocol in 
accordance with NIH and NHGRl regulations. (Note that all serious adverse 
events as defined fo r  this protocol must be reported in writing by mandated 
deadlines to the NHGRl Clinical Director, NHGRI IRB, and other agencies, i f  
pertinent.)
Not-applicable.
9.4 Describe whether a Data Safety and Monitoring Board (DSMB) will be used. 
Not-applieable.
10. Description of how privacy and confidentiality of medical
information/biological specimens will be maximized
10.1 Will participant identifiers be attached to data, or will samples/data be coded 
or unlinked.^ (Even i f  names are removed, how likely is potential 
identification ?)
10.2 Description o f any clinical/demographic information that will be included. 
{age, ethnicity, sex, diagnosis, stage, treatment)
10.3 How might this information make specific individuals or families identifiable?
10.4 If research data will be coded, how will access to the “key” for the code be 
limited? Include description of security measures {password-protected
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database, locked drawer, other). List names or positions o f persons with 
access to the key.
10.5 Will pedigrees be published? Include description o f measures to minimize the 
chance o f identifying specific families.
10.6 Will any results be provided to participants or their health care providers? 
Explain.
10.7 Will personally identifiable information be released to third parties?
10.8 Under what circumstances will data/samples be shared with other researchers?
10.9 Describe any additional features to protect confidentiality.
Only team members directly involved with your care and the research will have 
access to information, data, and results o f the study. All information and data 
from this study will be identified with a code number instead of your name. The 
key for this code will be stored in a locked file cabinet.
The pre and post Iodine-125 implant MR images of the prostate that we collect 
from you may be shared with other researchers in the future, linked together with 
other information such as your age, gender, and ethnicity. If this information is 
shared, we will not give other researchers your name, address, or phone number. 
Your name and all identifying information will be removed. There will be a code 
to link your data with your name and other personal information.
If future research on your pre and post Iodine-125 implant MR images o f the 
prostate provides important information related to your health, we will try to 
contact you. If you wish to be contacted, you must let Dr. Curtis Mack, MD at 
Arizona Oncology know about changes in your address or phone number.
11. Description of alternatives to participation (Other elinical or research 
interventions that participants should consider.)
Not-applieable.
12. Assessment of significance of study (Reasonableness o f  risks to participants in 
relation to the anticipated benefits o f  the study.)
The reasonable risk to participants is minimal since the pre operative Ultrasound and 
post-implant CT scan necessary for this study are part o f the standard treatment 
routine for prostate cancer patients. The only addition is the MRI studies to be done 
pre and post implant. MR imaging is safe and non-invasive, producing images with 
significant boundary definition o f prostate volumes. The benefits of having the same 
patients imaged pre and post-implant, is considerable when identifying volume 
differences in relation to total dose the prostate and surrounding tissue received in 
post-implant dosimetry analysis. If CT imaging is used as the sole means of
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evaluation in post-implant dosimetry, dose coverage o f the prostate will not be as 
accurate. Though techniques have been developed to improve CT post-implant 
dosimetry, we feel there is room for significant improvement.
13. Description of specific funding source and budget. (If project is funded from  P i ’s 
discretionary budget, this should ju st be noted without budget)
13.1 Clinical Center funds (clinical tests, nursing, in-patient days, etc.)
13.2 DIR resources (data management, statistics, non Clinical Center testing, and 
contracts.)
Funding for this research comes from the Northwest Medical Center.
14. Description of Consent Process
14.1 Who will obtain consent (PI, study coordinator, and primary physician)? If 
collaborators who are not designated as eo-investigators will be obtaining 
consent, the consent form should be signed by both the PI and the collaborator 
who is obtaining consent.
14.2 Setting where consent will be obtained (location o f  in-person discussion, 
phone, mail).
14.3 What information will be provided to participants? (Include consent form and 
any other related material, including information about stored tissues and 
pedigrees).
14.4 Protections for participants who may be vulnerable to coercion or undue 
influences (pregnant women, fetuses, children, people with impaired decision­
making ability).
14.5 Will children be studied? (Include c o w  of assent form).
14.6 Are there special circumstances regarding obtaining consent? (Waived 
consent, opt-out, verbal consent, consent with speakers o f  other languages 
and translation o f  materials into other languages.)
Participant’s consent will be obtained by Dr. Curtis Mack, MD, at Arizona 
Oncology, 1845 West Orange Grove, Building 1, 520-544-2919 during the 
initial volume study.
A Consent Form is included in this packet.
Participants unable to make rational decisions in regards to study participation 
will not be included.
(11/29/00)
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